

## Supplementary Materials

### Tissue fluidification promotes a cGAS/STING-mediated cytosolic DNA response in invasive breast cancer

Emanuela Frittoli<sup>1,†</sup>, Andrea Palamidessi<sup>1,†</sup>, Federica Zanardi<sup>1</sup>, Fabio Iannelli<sup>1</sup>, Stefano Villa<sup>2</sup>, Leonardo Barzaghi<sup>1</sup>, Hind Abdo<sup>1</sup>, Valeria Cancila<sup>3</sup>, Galina V. Beznuskenko<sup>1</sup>, Giulia della Chiara<sup>1</sup>, Massimiliano Pagani<sup>1,2</sup>, Chiara Malinverno<sup>1</sup>, Dipanjan Bhattacharya<sup>1</sup>, Federica Pisati<sup>1</sup>, Weimiao Yu<sup>4</sup>, Viviana Galimberti<sup>5</sup>, Giuseppina Bonizzi<sup>5</sup>, Emanuele Martini<sup>1</sup>, Alexander Mironov<sup>1</sup>, Ubaldo Gioia<sup>1</sup>, Fabrizio d'Adda di Fagagna<sup>1,6</sup>, Chiara Rossi<sup>7</sup>, Marco Lucioni<sup>7</sup>, Richard Tancredi<sup>8</sup>, Paolo Pedrazzoli<sup>8,9</sup>, Andrea Vecchione<sup>10</sup>, , Cristiano Petrini<sup>1</sup>, Francesco Ferrari<sup>1,6</sup>, Chiara Lanzuolo<sup>11</sup>, Guilherme Nader<sup>12</sup>, Marco Foiani<sup>1,13</sup>, Matthieu Piel<sup>12</sup>, Roberto Cerbino<sup>2,11</sup>, Fabio Giavazzi<sup>\*1,2</sup>, Claudio Tripodo<sup>\*1,3</sup> and Giorgio Scita<sup>\*1,13</sup>

**This PDF file includes:**

Materials and Methods

Figs. S1 to S11

Tables S1 to S7

References (85–112)

Movies S1 to S9

917 **Material and Methods**

918 **Antibodies and reagents**

919 920 REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Anti LaminB1	Abcam	Cat# ab16048
Anti LaminA/C	Santa Cruz Biotechnology	Cat# ab7292
Anti STAT2	Thermofisher	Cat# ab44-362G
Anti ISG15	Cell Signalling Technology	Cat# ab2743
Anti Vinculin	Sigma-Aldrich	Cat# abV9131
Anti RAB5A	Santa Cruz Biotechnology	Cat# ab309
Anti RAB5A	Abcam	Cat# ab109534
Anti phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)	Cell Signalling Technology	Cat# ab4370
Anti p44/42 MAPK (ERK1/2)	Cell Signalling Technology	Cat# ab9102
Anti p-STAT1 (58D6) (Tyr701)	Cell Signalling Technology	Cat# ab9167
Anti STAT1 (42H3)	Cell Signalling Technology	Cat# ab9175
FITC-conjugated Phalloidin	Sigma-Aldrich	Cat# P5282
Anti IRF3 (D614C)XP	Cell Signalling Technology	Cat# 11904
Anti STING/TMEM173	Novus Biologicals	Cat# NBP2-24683
Anti cGAS	Sigma-Aldrich	Cat# HPA031700
Anti IFIT1 (D2X9Z)	Cell Signalling Technology	Cat# 14769
Anti Istone H3 trimetil (Lys9)(D4W1U)	Cell Signalling Technology	Cat# 13969
Anti Istone H3 trimetil (Lys27)(C36B11)	Cell Signalling Technology	Cat# 9733
Anti fosfo $\gamma$ H2AX S139 (20E3)	Cell Signalling Technology	Cat# 9718
Anti-trimethyl-Histone H3 (Lys4)	Millipore	Cat#07-473
Anti-Histone H3 (acetyl K27) antibody	Abcam	Cat#4729
Anti-Histone H3 (tri methyl K9) antibody	Abcam	Cat#8898
Recombinant Anti-Histone H3 (tri methyl K9) antibody [EPR16601]	Abcam	Cat#ab176916
Anti 53BP1	Abcam	Cat# 175933
Anti p-CHK1	Abcam	Cat# ab58567
Anti $\alpha$ -Tubulin	Sigma-Aldrich	Cat# T5168
Anti YAP	Santa Cruz Biotechnology	Cat# 101199

Secondary Antibody (Goat Anti-Rabbit Antibody Conjugated to Horseradish Peroxidase)	Cell Signalling Technology	Cat# 7074
Secondary Antibody (Goat Anti-Mouse Antibody Conjugated to Horseradish Peroxidase)	Cell Signalling Technology	Cat# 7076
DAPI	Thermofisher	Cat# D-1306
Hoechst	Thermofisher	Cat# 62249
IncuCyte® NucLight Rapid Red dye	Sartorius	Cat# 4717
MitoTraker Red CMXRos	Thermofisher	Cat# M7512
Cy3 AffiniPure Donkey Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch	Cat# 711-165-152
Cy3 AffiniPure Donkey Anti-Mouse IgG (H+L)	Jackson ImmunoResearch	Cat# 715-165-150
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermofisher	Cat# A32790
Donkey anti-Mouse IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488	Thermofisher	Cat# A21202

### Chemicals

Latrunculin	Thermofisher	Cat# L12370
Etoposide	Selleckchem	Cat# S1225
Docetaxel	Selleckchem	Cat# S1148
Doxycycline hydrate	Sigma-Aldrich	Cat# D9891
SYBR Gold	Thermo-Fisher	Cat# S11494
Dynasore hydrate	Sigma-Aldrich	Cat# D7693
PD0325901	Sigma-Aldrich	Cat# 444968
Blebbistatin	Sigma-Aldrich	Cat# B0560
MK-886	Sigma-Aldrich	Cat# 475889
RU.521	Selleckchem	Cat# S6841
H <sup>15</sup> I	Selleckchem	Cat# S6652
MRT67307	Selleckchem	Cat# S7948

### Critical Commercial Assays

CometAssay® Kit	Trevigen	Cat# 4250-050-K
RNeasy mini kit	Qiagen	Cat# 74104
2'3'-cGAMP ELISA Kit	Cayman Chemical	Cat# 501700
SuperScript VILO cDNA Synthesis Kit	Thermofisher	Cat#11754050

### Oligonucleotides

siRNAs targeting MB21D1 (cGAS)	Horizon	Cat# L-015607-02-0010
siRNAs targeting TMEM173 (STING)	Thermofisher	Cat# s226307
siRNAs targeting IRF3	Thermofisher	Cat# s7507
siRNAs targeting IRF9	Thermofisher	Cat# s20292
siRNAs targeting STAT1	Thermofisher	Cat# s277

siRNAs targeting STAT2	Thermofisher	Cat# s13528
siRNAs targeting EZH2	Thermofisher	Cat# s4918
siRNAs targeting SUZ12	Thermofisher	Cat# s23968
siRNAs targeting TREX1	Horizon	Cat# L-013239-02-0010
siRNAs targeting YAP	Thermofisher	Cat# s20366
siRNAs targeting TAZ	Thermofisher	Cat# s13806

**qRT-PCR assays**

**Gene name**

Gene name	assay ID
18s	Hs99999901_s1
GAPDH	Hs99999905_m1
GUSB	Hs99999908_m1
HPRT	Hs99999909_m1
RAB5A	Hs00702360_s1
RAB5B	Hs00161184_m1
RAB5C	Hs00428044_m1
IFI27	Hs01086373_g1
IFI44	Hs00197427_m1
IFI44L	Hs00915292_m1
IFI6	Hs00242571_m1
IFIT1	Hs03027069_s1
IFIT3	Hs01922752_s1
ISG15	Hs01921425_s1
MX2	Hs01550814_m1
OASL	Hs00984387_m1
MB21D1 (cGAS)	Hs00403553_m1
TMEM173 (STING)	Hs00736958_m1
IRF3	Hs01547277_m1
IRF9	Hs00196051_m1
STAT1	Hs01013996_m1
STAT2	Hs01013115_g1
LMNA	Hs00153462_m1
LMNB1	Hs01059210_m1
EZH2	Hs01016789_m1
SUZ12	Hs00248742_m1
CDH1	Hs00170423_m1
AXIN2	Hs00610344_m1
CDH2	Hs00169953_m1
EGF	Hs01099999_m1
MMP13	Hs00942584_m1

ZEB1	Thermofisher	Hs00232783_m1
CTGF	Thermofisher	Hs00170014_m1
CYR61	Thermofisher	Hs00998500_g1
ANKRD1	Thermofisher	Hs00923602_g1
TREX1	Thermofisher	Hs03989617_s1
YAP	Thermofisher	Hs00902712_g1
TAZ	Thermofisher	Hs00179826_m1
Gapdh	Thermofisher	Mm99999915_g1
Gusb	Thermofisher	Mm01197698_m1
Hprt1	Thermofisher	Mm00446968_m1
Cxcl10	Thermofisher	Mm00445235_m1
Ifi35	Thermofisher	Mm01260550_g1
Ifit1	Thermofisher	Mm00515153_m1
Irf7	Thermofisher	Mm00516793_g1
Irf9	Thermofisher	Mm00492679_m1
Isg15	Thermofisher	Mm01705338_s1
Oas3	Thermofisher	Mm00460944_m1
Stat1	Thermofisher	Mm00439531_m1
Stat2	Thermofisher	Mm00490880_m1
Rab5a	Thermofisher	Mm01278246_m1

921  
922

## Cell cultures and transfection

923 MCF10.DCIS.com cells were provided by J. F. Marshall (Barts Cancer Institute, Queen Mary University of  
924 London, UK) and maintained in DMEM/F12 (Biowest) supplemented with 5% horse serum (Life  
925 Technologies), 2 mM L-Glutamine (EuroClone), 0.5 mg/ml Hydrocortisone (Sigma-Aldrich),  
926 10 µg/ml Human insulin (Sigma-Aldrich) and 20 ng/ml EGF (Peprotech).

927 MCF10A cells were a gift from J. S. Brugge (Department of Cell Biology, Harvard Medical School, Boston,  
928 USA) and were maintained in DMEM/F12 (Biowest) supplemented with 5% horse serum (Life  
929 Technologies), 2 mM L-Glutamine (EuroClone), 0.5 mg/ml Hydrocortisone (Sigma-Aldrich),  
930 100 ng/ml cholera toxin (Sigma-Aldrich), 10 µg/ml Human insulin (Sigma-Aldrich) and 20 ng/ml EGF  
931 (Peprotech).

932 SUM225 CWN (Asterand) were maintained in Ham's F12 (Life Technologies) + 5% FBS (Life Technologies)  
933 + 10 mM Hepes (EuroClone) + 5 µg/ml Human Insulin (Sigma-Aldrich) + 1 µg/ml Hydrocortisone (Sigma-  
934 Aldrich) + 2 mM L-Glutamine (EuroClone).

935 4T1 (ATCC) were maintained in RPMI 1640 (Lonza) + 10% FBS (Life Technologies) + 2 mM L-Glutamine  
936 (EuroClone).

937 HaCaT (ATCC) were maintained DMEM (Lonza) + 10% FBS (Life Technologies) + 2 mM L-Glutamine  
938 (EuroClone).

939 Phoenix-AMPHO cells (American Type Culture Collection, CRL-3213) were used as the packaging cell line  
940 for the generation of retroviral particles and cultured as recommended by the supplier.

941 HEK293T (BBCF-Biological Bank and Cell factory, INT, Milan) were grown in DMEM (Lonza) supplemented  
942 with 10% FBS (Life Technologies) and 2 mM L-Glutamine (EuroClone) and used as the packaging line for  
943 lentiviral vectors.

944 MCF10A cells were infected with pSLIK-neo-EV (empty vector, CTR) or pSLIK-neo-RAB5A lentiviruses and  
945 selected with the appropriate antibiotic to obtain stable inducible cell lines. MCF10.DCIS.com were infected  
946 with pSLIK-hygro-RAB5B, pSLIK-neo-RAB5C, pSLIK-neo-EV (empty vector, CTR) or pSLIK-neo-RAB5A  
947 lentiviruses and selected with the appropriate antibiotic to obtain stable inducible cell lines. Constitutive  
948 expression of mCherry H2B was achieved by retroviruses infection of MCF10DCIS.com cells with pBABE-

949 puro-mCherry-H2B vector. pLL5.0 E-Cadherin shRNA/mEcad-GFP vector was a gift from Alpha S. Yap  
950 (Division of Molecular Cell Biology, Institute for Molecular Bioscience, The University of Queensland,  
951 Australia). pTRIP-CMV-GFP-FLAG-cGAS GFP vector was from Addgene (plasmid# 86675). pTRIP-SFFV-  
952 EGFP-NLS vector was from Addgene (plasmid# 86677).

953 Transfections were performed using either calcium phosphate or FuGENE HD Transfection Reagent  
954 (Promega, Cat# E2311), according to the manufacturer's instructions.

955 All cell lines have been authenticated by cell fingerprinting and tested for mycoplasma contamination. Cells  
956 were grown at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>.

957 **Generation of lentiviral and retroviral particles**

958 Packaging of lentiviruses or retroviruses was performed following standard protocols. Viral supernatants  
959 were collected and filtered through 0.45 µm filters. Cells were subjected to four cycles of infection and  
960 selected using the appropriate antibiotic: neomycin for the pSLIK-neo vector (150 µg/ml), hygromycin for  
961 the pSLIK-hgro vector (100 µg/ml) or puromycin for the pBABE vector (2 µg/ml). After several passages,  
962 stable bulk populations were selected and induced by doxycycline hyclate (2.5 µg/ml) in order to test: (1)  
963 induction efficiency by western blotting and quantitative reverse-transcription polymerase chain reaction  
964 (qRT-PCR), and (2) the homogeneity of the cell pool.

965 **RNA interference**

966 siRNA delivery was achieved by mixing 50 nM of specific siRNAs with Optimem and Lipofectamine  
967 RNAiMAX Transfection Reagent (Thermofisher, Cat# 13778150). The first cycle of interference (reverse  
968 transfection) was performed on cells in suspension. The day after, a second cycle of interference (forward  
969 transfection) was performed on cells in adhesion. The siRNAs used for knocking down specific genes are  
970 reported reagents' table. For each RNA interference experiment, a negative control was performed with the  
971 same amounts of scrambled siRNAs. Silencing efficiency was controlled by qRT-PCR.

972 **Quantitative RT-PCR analysis**

973 Quantitative RT-PCR analysis was performed as previously described<sup>85</sup>. Total RNA was extracted using the  
974 RNeasy Mini kit and quantified by NanoDrop to assess both concentration and quality of the samples.  
975 Reverse transcription was performed using the SuperScript VILO cDNA Synthesis kit. Gene expression  
976 was analysed by using the TaqMan Gene expression Assay (Applied Biosystems). 0.1 ng of cDNA was  
977 amplified, in triplicate, in a reaction volume of 25 µl with 10 pmol of each gene-specific primer and the SYBR  
978 Green PCR MasterMix (Applied Biosystems). Real-time PCR was performed on the 14 ABI/Prism 7700  
979 Sequence Detector System (PerkinElmer/Applied Biosystems) using a pre-PCR step of 10 min at 95 °C,  
980 followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C. Specificity of the amplified products was confirmed  
981 by melting curve analysis (Dissociation Curve TM; Perkin Elmer/Applied Biosystems) and by 6% PAGE.  
982 Preparations with RNA template without reverse transcription were used as negative controls. Samples  
983 were amplified with primers for each gene and different housekeeping genes. The cycle threshold Ct values  
984 were normalized to the housekeeping gene curve. PCR experiments were performed in triplicate and  
985 standard deviations calculated and displayed as error bars. List of qRT-PCR assays is reported in reagents'  
986 table.

987 **Immunoblotting**

988 Cells, washed twice with cold phosphate-buffered saline (PBS), were lysed in JS buffer supplemented with  
989 proteases and phosphatases inhibitors (50 mM HEPES pH 7.5, 50 mM NaCl, 1% glycerol, 1% Triton X-100,  
990 1.5 mM MgCl<sub>2</sub>; 5 mM EGTA, protease inhibitor cocktail (Roche Basel, Switzerland), 20 mM Na  
991 pyrophosphate pH 7.5, 50 mM NaF, 0.5 M NaVO<sub>4</sub> in HEPES pH 7.5 to inhibit phosphatases). Lysates were  
992 incubated on ice for 15 min and cleared by centrifugation at 13000 r.p.m. for 30 min at 4 °C. Protein  
993 concentration was quantified by the Bradford colorimetric protein assay. The same amount of protein  
994 lysates was loaded into polyacrylamide gel in 5X SDS sample buffer. Proteins were transferred onto Protran  
995 Nitrocellulose Transfer membranes (Whatman), probed with the appropriate antibodies (reported in  
996 reagents' table) and visualized with ECL western blotting detection reagents (GE Healthcare). Incubation  
997 in primary antibodies were performed for ON at 4 °C in TBS/0.1% Tween/5% milk for antibodies recognizing  
998 the total proteins or in TBS/0.1% Tween/5% bovine serum albumin (BSA) for antibodies recognizing  
999 phosphorylated proteins.

1000 **Tissue collection**

1006 Breast biopsies were collected from women undergoing mastectomy for primary breast cancer. Donors  
1007 were informed before the surgery and agreed by written consent to donate tissues. The use of human  
1008 material has been reviewed by European Institute of Oncology Ethical Committees (reference to UID 2152).  
1009 The permit for obtaining clinical material did not include access to basic information regarding patients and  
1010 their detailed medical histories are not given to the authors. Tumor biopsies were processed immediately  
1011 upon receipt and cultured as described below.

1012

1013 **Organoids' culture**

1014 Organoids were prepared exactly as described previously<sup>86</sup>. In short, cells freshly isolated from human  
1015 breast cancer tissues listed in the table below were embedded in 10 mg/ml cold Cultrex growth factor  
1016 reduced BME type 2 and 80  $\mu$ L drops of BME-cell suspension were allowed to solidify on prewarmed 24-  
1017 well CELLSTAR culture plates (Greiner, Cat#662102) at 37°C for 30 min. Upon completed gelation, 500  $\mu$   
1018 l of BC organoid medium was added to each well and plates transferred to humidified 37°C / 5%  
1019 CO<sub>2</sub> incubator. Medium was changed every 4 days. Live-cell imaging was done using a confocal  
1020 microscope equipped with a gas incubation system for CO<sub>2</sub>. Organoids were labeled with IncuCyte®  
1021 NucLight Rapid Red dye (1: 500) for nuclei visualization.

1022

1023

Sample N.	TYPE	TISSUE TYPE	DIAGNOSIS	ER (%)	PGR (%)	HER2 SCORE	HER2 %	KI67 (%)
BR 25	Pathological	Breast - Left	Infiltrating duct carcinoma	60	60	Neg		4
BR 30	Pathological	Breast - Right	Infiltrating duct carcinoma	90	90	3+	90	28
BR 39	Pathological	Breast - Left	Infiltrating duct carcinoma	95	95	Neg		12
BR 40	Pathological	Breast - Right	Cribriform carcinoma	95	30	1+	15	3
BR 44	Pathological	Breast - Right	Infiltrating duct carcinoma	95	40	Neg		22

1024

### 1025 Transcriptomics analyses

1026 Control and RAB5A-expressing monolayers MCF10A or MCF10.DCIS.com cells were seeded in six-well  
1027 plates ( $1.5 \times 10^6$  cells per well) and cultured until a uniform monolayer had formed. Three independent  
1028 biological replicas were performed for all this analysis. RAB5A expression was induced, by adding fresh  
1029 complete media supplemented with 2.5  $\mu$ g/ml doxycycline hydiate to cells. Comparable cell confluence was  
1030 tested by taking pictures by differential interference contrast imaging using a 10 $\times$  objective and counting  
1031 the number of nuclei per field. After 48 h monolayers were processed for RNA extraction using TRIzol  
1032 reagent (Thermo Fisher) and processed for total RNA extraction with PureLink<sup>TM</sup> RNA Mini Kit (Thermo  
1033 Fisher), according to manufacturer's instructions.

1034 For RNA-seq analysis of breast cancer patients derived organoids, matrigel droplets containing  
1035 organoids were directly lysed as described above. The RNA quality was assessed by the RNA Integrity  
1036 Number (RIN) value with RNA 6000 Nano kit assay (Agilent). Only samples with RIN > 8.0 were used in  
1037 this study. RNA-seq libraries were constructed according to the TruSeq mRNA Stranded preparation kit  
1038 (Illumina, San Diego, USA) and sequenced at HiSeq2500.

1039 *Libraries for mRNA-Seq:* mRNA-seq indexed library preparation was performed starting from 500 ng of  
1040 total mRNA (Illumina, TruSeq Stranded mRNA, 20020594) according to the manufacturer's instructions.  
1041 Indexed libraries were quality controlled on Agilent Bioanalyzer 2100 (High Sensitivity DNA kit), quantified  
1042 (Qubit dsDNA HS Assay, Q32851), normalized and pooled to perform a multiplexed sequencing run. 1%  
1043 PhiX control was added to the sequencing pool, to serve as a positive run control. Sequencing was  
1044 performed in PE mode (2x75nt) on an Illumina NextSeq550 platform, generating on average 50 million PE  
1045 reads per sample. Experiment was performed using biological triplicates; a total of 12 samples were  
1046 sequenced.

1047 Reads were aligned to the GRCh38/hg38 assembly human reference genome using the STAR aligner<sup>87</sup>  
1048 with default settings with the parameter --quantMode GeneCounts in order to obtain gene counts.  
1049 Differential gene expression analysis was performed using the Bioconductor package DESeq2<sup>88</sup> that  
1050 estimates variance-mean dependence in count data from high-throughput sequencing data and tests for  
1051 differential expression exploiting a negative binomial distribution-based model. Preranked gene set

enrichment analysis (GSEA) for evaluating pathway enrichment in transcriptional data was carried out using the Bioconductor package fgsea<sup>89</sup>, taking advantage of the Hallmarks, KEGG and chemical and genetic perturbations (CGP) gene sets available from the GSEA Molecular Signatures Database (<http://www.gsea-msigdb.org/gsea/msigdb/collections.jsp>).

Transcription factor enrichment analysis for overlap between the input set of differentially expressed genes and entries of the ChEA and ENCODE databases was performed using the Transcription Factor Enrichment Analysis tool from the X2K Web suite (<https://maayanlab.cloud/X2K/>) that infers upstream regulatory networks from lists of differentially expressed genes.

### 1061 **Chip-Seq experiments**

1062 Control or RAB5A-expressing MCF10 DCIS.com monolayers were treated with Formaldehyde (F8775  
1063 SIGMA) in a PBS-solution (final 1%) for 10 min while rocking at room temperature and quenched with 0.125  
1064 M Glycine for 5 min. Cells were washed twice with cold PBS and scraped off the plates. PBS-washed cells  
1065 were transferred to 15 ml tubes and spun down at 400g at 4C. The pellet was lysed with 1X sonication lysis  
1066 buffer (10 mM Tris pH 8.0, 0.25% SDS, 2 mM EDTA, plus protease inhibitors) and incubated for at least 10  
1067 min at 4°C. Lysed chromatin was sheared at the average size of 300 bp fragments using Covaris® E220  
1068 evolution ultrasonicator (settings: duty factor 20%, peak incidence power 75 Watt, cycles per burst 200, 5  
1069 minutes). Sonicated chromatin (3 mg) was incubated overnight at 4°C with 3 mg of the following histone  
1070 mark antibodies: H3K9me3 ab176916, H3K9me3 ab8898. Immunocomplexes were recovered with 20 µl of  
1071 pre-blocked Protein G-Dynabeads (Thermo Fisher) for 2 h, at 4°C, and washed twice with RIPA-low salt,  
1072 twice with RIPA-high salt, twice with RIPA-LiCl and once with 10 mM Tris pH 8.0 and once with 1X TE, as  
1073 previously reported<sup>90</sup>. The washed immunocomplexes were incubated with ChIP elution buffer (10 mM Tris-  
1074 HCl pH 8.0, 5 mM EDTA pH 8.0, 300 mM NaCl, 0.4% SDS) supplemented with 0.8 mg/ml Proteinase K for  
1075 1 h at 55°C and overnight at 65°C, for reverse crosslinking. The immunoprecipitated DNA was then purified  
1076 by Qiagen MinElute kit (Qiagen) and eluted in 22 µl EB buffer. ChIP-seq libraries were constructed with  
1077 TruSeq ChIP Library Preparation Kit (Illumina), according to the manufacturer's instructions and sequenced  
1078 on Illumina HiSeq2500 platform.

1079 *Libraries for ChIP-Seq:* 2 ng of DNA having fragment size 350-400bp were used to synthesize libraries for  
1080 Chromatin Immunoprecipitation profiles (Kapa HyperPrep kit; Roche KK8504, KK8727). Indexed DNA  
1081 libraries were size-selected and purified (AmpureXP, Beckman, A63881), quantitated (Qubit dsDNA HS  
1082 Assay, Q32851), checked for size distribution on Agilent Bioanalyzer 2100 (DNA HS kit, Agilent, 5067-  
1083 4626) and normalized for pooling. 1% PhiX control was added to the sequencing pool, to serve as a positive  
1084 run control. Sequencing was performed in SR mode (1x75nt) on an Illumina NextSeq550 platform,  
1085 generating on average 35 million SR reads per sample. A total of 14 samples were sequenced

### 1086 **SAMMY-seq experiments.**

1088 Three distinct biological replicas of control and RAB5A expressing MCF10.DCIS.com monolayers were  
1089 processed for chromatin fractionation as described<sup>91</sup>, with minor adaptions. Briefly, 3 million cells were  
1090 washed in PBS 1X, and extracted in 600 µl of cytoskeleton buffer (CSK: 10 mM PIPES pH 6,8; 100 mM  
1091 NaCl; 1 mM EGTA; 300 mM Sucrose; 3 mM MgCl2; 1X protease Inhibitors by Roche Diagnostics; 1 mM  
1092 PMSF) supplemented with 1 mM DTT and 0,5% Triton X-100. After 10 min on wheel at 4°C the cytoskeletal  
1093 structure was separated from soluble proteins by centrifugation at 900g for 3' at 4°C, and the supernatant  
1094 was labeled as S1 fraction. The pellets were resuspended with 600 µl of cytoskeleton buffer, put 10 min on  
1095 wheel at 4°C followed by centrifugation at 900g for 3' at 4°C. Chromatin was solubilized by DNA digestion  
1096 with 25U of RNase-free DNase (Turbo DNAse; Invitrogen AM2238) in 100 µl of CSK buffer for 60 min at  
1097 37°C. To stop digestion, ammonium sulphate was added in CSK buffer to a final concentration of 250 mM  
1098 and, after 5' in ice samples were pelleted at 900g for 3 min at 4°C and the supernatant was labeled as S2  
1099 fraction. The pellets were resuspended with 200 µl of CSK buffer, put 10 min on wheel at 4°C followed by  
1100 centrifugation at 3000g for 3 min at 4°C. The pellet was further extracted with 100 µl of CSK buffer with 2M  
1101 NaCl for 5 min at 4°C, centrifuged at 2300g 3 min at 4°C and the supernatant was labeled as S3 fraction.  
1102 This treatment removed the majority of histones from chromatin. The pellets were washed twice with 200  
1103 µl of CSK buffer with 2M NaCl, put 10 min on wheel at 4°C followed by centrifugation at 3000g for 3 min at  
1104 4°C., The pellets were solubilized in 100 µl of 8M urea buffer for 10 min at room temperature to remove any  
1105 remaining protein component by applying highly denaturing conditions. This fraction was labeled as S4.  
1106 DNA was extracted from S2, S3 and S4 fractions. All fractions were quantified and analyzed by SDS-PAGE  
1107 and immunoblotting. Anti-tubulin alpha (Sigma T5168, mouse 1:10000), H3 (Abcam ab1791, rabbit 1:4000),

1108 Beta-Actin (Santa-Cruz sc1616, rabbit 1:4000), were used as primary antibodies. HRP-conjugated  
1109 secondary antibodies were revealed with the ECL chemiluminescence kit (Thermo Fisher Scientific).  
1110

1111 After incubation 90 min at 37°C with 6 µl of RNase cocktail (Invitrogen AM2286) followed by 150 min  
1112 at 55°C with 40 mg of Proteinase K (Invitrogen, AM2548), DNA was extracted by standard  
1113 phenol/chloroform extraction, precipitated and resuspended in 15µl milliQ H2O. The S2 fraction was further  
1114 purified with PCR DNA Purification Kit (Qiagen, 28106). After Qubit HS DNA quantification then samples  
1115 were evaluated by capillary electrophoresis (Agilent 2100 Bioanalyzer) and then sonicated with a Covaris  
1116 M220 Focused-ultrasonicator using screw cap microTUBEs with the parameters: water bath 20°C, peak  
1117 power 30.0, duty factor 20.0, cycle/burst 50, duration: 125 seconds for S2 and S3 fractions, 150 seconds  
1118 for S4 fraction. The DNA profiles were checked again by capillary electrophoresis (Agilent 2100  
1119 Bioanalyzer).

1120 *Libraries for SAMMY-Seq:* for fractions S2, S3 and S4 obtained from chromatin fractionation  
1121 procedure, at least 2.5 ng DNA were used to generate an indexed library (Kapa HyperPrep kit; Roche  
1122 KK8504, KK8727). Indexed DNA libraries were purified (AmpureXP, Beckman, A63881), quantitated (Qubit  
1123 dsDNA HS Assay, Q32851), checked for size distribution on Agilent Bioanalyzer 2100 (DNA HS kit, Agilent,  
1124 5067-4626) and normalized for pooling. 1% PhiX control was added to the sequencing pool, to serve as a  
1125 positive run control. Sequencing was performed in SR mode (1x75nt) on an Illumina NextSeq550 platform,  
1126 generating at least 30 million SR reads per sample. Experiment was performed using biological triplicates;  
1127 A total of 18 samples were sequenced

#### 1128 *SAMMY-seq and ChIP-seq data analysis*

##### 1129 *Preprocessing of sequencing reads*

1130 Sequencing reads were trimmed and adapters removed by using Trimmomatic (v0.39)<sup>92</sup> using the following  
1131 parameters for SAMMY-seq and ChIP-seq data: 2 for seed\_mismatch, 30 for palindrome\_threshold, 10 for  
1132 simple\_threshold, 3 for leading, 3 for trailing and 4:15 for sliding window and sequence minimum length  
1133 threshold of 35. As clip file has been used the trimmomatic provided dataset "TruSeq3-SE.fa" (for single  
1134 end). In addition, only for SAMMY-seq data, all reads were cropped to 75 bp reads length (if longer) by  
1135 setting the crop option of Trimmomatic (v0.39) to 75. After trimming, the reads were aligned using BWA  
1136 (v0.7.17-r1188)<sup>93</sup> setting -k parameter as 2 and using as reference genome the UCSC hg38 one (only  
1137 canonical chromosomes have been taken into consideration). The alignment duplicates have been marked  
1138 with Picard (v2.22) (<http://broadinstitute.github.io/picard/>) MarkDuplicates option. And then filtered using  
1139 Samtools (v1.9)<sup>94</sup>, in addition we filtered all the reads with mapping quality lower than 1, unmapped and  
1140 read fails platform/vendor quality checks (-F 1540 -q 1).  
1141 Each sequencing lane has been analysed separately up to this point and then merged.

##### 1142 *Genomic tracks for data visualization*

1143 The comparison between sequencing reads enrichment in ChIP-seq (ChIP over input control reads  
1144 enrichment) or SAMMY-seq fractions comparison was performed using the SPP (v1.16.0)<sup>95</sup> (v3.5.2) library.  
1145 The reads have been imported from the (previously filtered) bam files using the "read.bam.tags" function,  
1146 then they were filtered using "remove.local.tag.anomalies" and finally the normalized log2 reads density  
1147 ratio was computed using the function "get.smoothed.enrichment.mle" setting "tag.shift = 0" and  
1148 "background.density.scaling = TRUE" to exclude enriched regions from the calculation of normalization  
1149 scaling factor.  
1150 The comparisons between sequencing reads enrichment were graphically plot using the R (v3.5.2) library  
1151 Gviz (1.26.5) setting 1000 as number of represented points ("window" parameter).

##### 1152 *Heterochromatin domains calling*

1153 Heterochromatin (H3K9me3 enriched) domains were defined using the EDD (v1.1.19)<sup>96</sup> software with  
1154 parameters (binsize = 200 Kb and gap penalty = 25) processing the filtered bam files obtained as described  
1155 above. The "required\_fraction\_of\_informative\_bins" parameter was set to 0.98. The unalignable regions  
1156 were defined with the ENCODE Unified GRCh38 Exclusion List (previously "blacklist") and downloaded  
1157 from (<https://www.encodeproject.org/files/ENCFF356LFX/>).

##### 1158 *Metaprofile analysis*

1159 The metaprofile analysis was performed using DeepTools (v3.4.3)<sup>97</sup>. The metaprofile matrix was calculated  
1160 using the "computeMatrix" command of DeepTools, using as regions of interest the heterochromatin  
1161

1165 domains obtained from CTR H3K9me3 ChIP-seq experiment (with antibody ab-176916-Abcam), as  
1166 described above, and as signal the S4/S2 or the S4/S3 SAMMY-seq fractions comparisons (log2 ratios)  
1167 calculated with SPP, as described above. The domains flanking regions (upstream and downstream) were  
1168 defined of a size of 1 Mb and 20 Kb was chosen as bin size for each bin representing the domain ("binSize"  
1169 parameter) and the target size of the domains rescaling was defined as 3 Mb. In addition, the "skipZeros"  
1170 option was added to remove regions with zero reads coverage. The metaprofile matrix was represented  
1171 using the "plotProfile" tool of DeepTools using as input the previously created matrix.  
1172

### 1173 Immunohistochemistry on DCIS and IDC

#### 1174 Immunolocalization analysis of mouse and human tissues sections

1175 Four-micrometers-thick human and mouse tissue sections were deparaffinized, rehydrated and unmasked  
1176 using Novocastra Epitope Retrieval Solutions pH6 or pH9 in thermostatic bath at 98°C for 30 minutes.  
1177 Subsequently, the sections were brought to room temperature and washed in PBS. After neutralization of  
1178 the endogenous peroxidase with 3% H<sub>2</sub>O<sub>2</sub> and Fc blocking by a specific protein block (Leica Novocastra),  
1179 the samples were incubated with the following primary antibodies: RAB5A (clone EPR5438, 1:100 pH6,  
1180 ab109534, Abcam), phospho-γH2AX (1:1000 pH6, ab11174, Abcam), cGAS (clone D1D3G, 1:100 pH6,  
1181 #15102, Cell Signaling), pCHK1 (1:500 pH9, ab58567, Abcam).

1182 IHC staining for cGAS was revealed using Novolink Polymer Detection Systems (Leica Novocastra) and  
1183 DAB (3,3'-Diaminobenzidine, Leica Novocastra) as substrate chromogen and the slides were  
1184 counterstained with Harris hematoxylin (Novocastra).

1185 For multiple-marker immunostainings, in order to multiplex antibodies raised in the same species, Opal  
1186 Multiplex IHC kit was developed. After deparaffinization, antigen retrieval in pH6 buffer was brought to a  
1187 boil at 100% power, followed by 20% power for 15 minutes using microwave technology (MWT). Sections  
1188 were treated with blocking buffer for 10 minutes at room temperature before primary antibody incubation.  
1189 Slides were then incubated with Polymeric horseradish peroxidase-conjugated (HRP) secondary antibody  
1190 for 10 minutes and the signal was visualized using Opal 520 fluorophore-conjugated tyramide signal  
1191 amplification (TSA) at 1:100 dilution. The HRP catalyze covalent deposition of fluorophores around the  
1192 marker of interest. The slides were again processed with the microwave treatment to strip  
1193 primary/secondary antibody complex and allow the next antigen-antibody staining. Another round of  
1194 staining was performed with the second primary antibody incubation, followed by Polymeric horseradish  
1195 peroxidase-conjugated (HRP) secondary antibody and Opal 620 fluorophore-conjugated tyramide signal  
1196 amplification (TSA) at 1:100 dilution for signal visualization. Finally, slides were again microwaved in  
1197 antigen retrieval buffer and nuclei were subsequently visualized with DAPI (4',6-diamidin-2-fenilindolo). All  
1198 slides were analyzed under a Zeiss Axioscope A1 microscope equipped with four fluorescence channels  
1199 widefield IF. Microphotographs were collected using a Zeiss Axiocam 503 Color digital camera with the Zen  
1200 2.0 Software (Zeiss).  
1201

#### 1202 Quantification of γH2AX in human primary tumor samples

1203 We used a semi-automated image analysis pipeline to quantify the location of the γH2AX expressing cells  
1204 in the tumoral ductaladenocarcinoma regions. Specifically, we employed a deep learning based nuclear  
1205 segmentation (Stardist)<sup>98</sup> to segment individual nuclei and identified the centroid positions of each nuclei in  
1206 the image frame. A semi-automated analysis was used to identify the location of whole area, the core region  
1207 and the outer margin of the ductaladenocarcinoma. The proper assignment of these regions was verified  
1208 by a trained pathologist. In all cases, we removed the segmented nuclei with a centroid 20 pixels from the  
1209 border regions of the imaging frame. We used an automated histogram-based thresholding in each frame  
1210 to identify regions with high expression of γH2AX signal, above the threshold applied. We also removed  
1211 isolated small spots as noise. Next, we identified the nuclei that display either a positive or weak/absent  
1212 (below the arbitrary established threshold levels) γH2AX signal. For each case, we quantified the total  
1213 number of nuclei, the number of nuclei with strongly positive or weak/no γH2AX signal in the tumor core,  
1214 tumor surface and in the whole tumoral areas and computed the percentage of nuclei with strongly positive  
1215 γH2AX signal in the core region, tumor front regions and in the whole tumor region over 9 independent  
1216 cases. The whole image analysis pipeline is presented in Movie S9.

1217 For the quantification of the percentage of RAB5A-positive displaying γH2AX positive or cGAS positive  
1218 signals. After semiautomated identification the whole area, the core region and the outer margin of the  
1219 ductaladenocarcinomas, as described above, the percentage of cells in the various areas expressing  
1220 express high (>2 on scale from 0.1,2,3) or low ( < 2 on scale from 0.1,2,3) levels of RAB5A identified by  
1221 expert pathologists and positive for either γH2AX positive or cGAS was counted.

1222

1223

### Cell streaming assay

As previously shown<sup>85</sup>, cells were seeded in six-well plates ( $1.5 \times 10^6$  cells per well) in complete medium and cultured until a uniform monolayer had formed. RAB5A expression was induced, where indicated, 16 h before performing the experiment by adding fresh complete media supplemented with 2.5  $\mu$ g/ml doxycycline hydiate to cells. Comparable cell confluence was tested by taking pictures by differential interference contrast imaging using a 10 $\times$  objective and counting the number of nuclei per field. In the cell streaming assay, the medium was refreshed before imaging began. An Olympus ScanR inverted microscope with 10 $\times$  objective was used to take pictures every 5-15 min over a 24h-48h period. The assay was performed using an environmental microscope incubator set to 37 °C and 5% CO<sub>2</sub> perfusion. After cell induction, doxycycline hydiate was maintained in the media for the total duration of the time-lapse experiment.

For plasma membrane tension perturbation by osmotic treatments, an equal volume of hypotonic buffer (H<sub>2</sub>O + 1 mM CaCl<sub>2</sub> + 1 mM MgCl<sub>2</sub>) was added to cell monolayer before performing experiments.

1234

1235

1236

### 3D spheroid formation assay

MCF10.DCIS.com cells were plated on ultra-low-attachment-surface six-well plates (Corning, Cat# 3471) at a density of  $5 \times 10^3$  cells per well. Cells were grown in serum-free condition for 10 days by adding fresh culture media every 2 days. After 7 days, 2.5  $\mu$ g/ml doxycycline hydiate was added to the medium to induce RAB5A expression. Doxycycline was maintained in the medium for two days and finally spheroids were collected and processed for total RNA extraction.

1237

1238

1239

1240

1241

1242

1243

### Mammary fat pad tumor development in NSG mice.

All animal experiments were approved by the OPBA (Organisms for the well-being of the animal) of IFOM and Cogentech. All experiments complied with national guidelines and legislation for animal experimentation. All mice were bred and maintained under specific pathogen-free conditions in our animal facilities at Cogentech Consortium at the FIRC Institute of Molecular Oncology Foundation and at the European Institute of Oncology in Milan, under the authorization from the Italian Ministry of Health (Autorizzazione N° 604-2016).

Control and RAB5A MCF10.DCIS.com were injected into female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (commonly known as the NOD SCID gamma; NSG) mice as described previously<sup>99</sup>. Before injection, control or RAB5A-expressing MCF10.DCIS.com cells were trypsin detached, washed twice and resuspended at a final concentration of 300000 cells/13  $\mu$ l PBS. The cell suspension was then mixed with 5  $\mu$ l growth factor-reduced Matrigel (BD, Cat# 354263) and 2  $\mu$ l Trypan blue solution and maintained on ice until injection. Aseptic conditions under a laminar flow hood were used throughout the surgical procedure. Female NSG mice, 6–9 weeks-old, were anesthetized with 2% isoflurane and injected with a 20 $\mu$ l cell suspension directly in the fourth mammary fat pad. Mice were fed with doxycycline hydiate 4 days after injection. Tumor growth was monitored weekly using digital calipers, and tumor volume was calculated according to the formula: L  $\times$  W<sup>2</sup>/2 = mm<sup>3</sup>. After 3 weeks, mice were anesthetized with 2% isoflurane to remove primary tumors (mastectomy). For histological evaluation, primary tumors were fixed in 4% phosphate-buffered formalin and embedded in paraffin. 3- $\mu$ m sections of tumors were made and slides were counterstained with H&E and with indicated antibodies. Fragments of primary tumors were snap frozen on dry ice and stored at -80°C before mRNA analysis. For ex vivo MCF10.DCIS.com tumor slices, primary tumors were removed, cut by a scalpel and each tumor slide was placed over a metal grid inserted in a six-well plate to allow tumors to grow on an interface air/culture medium. Before imaging, 2.5  $\mu$ g/ml doxycycline hydiate was added to the tumor slices culture media to induce RAB5A expression. Tumor cells were maintained under stimulation for five days, changing the medium every day. Tissue samples were fixed in 10% buffered formalin and embedded in paraffin. 4- $\mu$ m tissue sections were counterstained with H&E and with indicated antibodies.

1271

1272

### Neutral comet assay

Neutral comet assay was performed as already described<sup>100</sup> following the manufacturer's protocol (Trevigen). In summary, MCF10.DCIS.com cell monolayers were harvested by trypsinization, washed once in ice-cold PBS and resuspended in cold PBS at the final concentration of  $1 \times 10^5$  cells/ml. Cell suspension was mixed with low-melting agarose at a ratio of 1:10 (v/v) and loaded onto comet slides. Samples were lysed in Lysis Solution over-night at 4 °C. Following electrophoresis in 1X Neutral Electrophoresis Buffer for 45 min at 21 V, slides were incubated in DNA Precipitation Buffer and washed once in 70% ethanol. Slides

1279 were then dried up and DNA stained with SYBR Gold (Thermo-Fisher) prior to imaging. Comet tail moment  
1280 was measured using OpenComet plug-in for ImageJ<sup>101</sup>.  
1281

### 1282 **Laser-induced nuclear rupture and live-cell imaging**

1283 Cells were seeded on glass coverslips and cultured in complete medium until a uniform monolayer had  
1284 formed. Cell culture medium has been refreshed before the live-imaging session.  
1285

1286 Laser-induced nuclear rupture experiments were performed on an UltraVIEW VoX spinning-disk confocal  
1287 system (PerkinElmer) equipped with an EclipseTi inverted microscope (Nikon) provided with a Nikon  
1288 Perfect Focus System, an integrated FRAP PhotoKinesis unit (PerkinElmer) and a Hamamatsu CCD  
1289 camera (C9100-50) and driven by Velocity software (Improvision; Perkin Elmer). All images were acquired  
1290 through a 60X oil-immersion objective (Nikon Plan Apo VC, NA 1.4). After defining the region of interest,  
1291 pre bleach images were collected for 30 seconds at a rate of 5 seconds per timepoint. Photobleaching was  
1292 performed using UltraVIEW PK Device as a bleaching device on a small spot over the nuclear envelope.  
1293 Images were captured for 300 seconds at a rate of 5 seconds per timepoint.  
1294

### 1295 **Image acquisition**

1296 Time-lapse imaging of the motility of 3D organoids was performed using a Leica TCS SP8 laser confocal  
1297 scanner mounted on a Leica DMI8 microscope equipped with motorized stage; a HC PL FLUOTAR 20×/0.5  
1298 NA dry objective was used. A white-light laser was used as the illumination source. Leica Application Suite  
1299 X (LAS X, <https://www.leicamicrosystems.com/products/microscopesoftware/details/product/leica-las-x-ls/>) was the software used for all the acquisitions. Image acquisition conditions were set to remove channel  
1300 crosstalk, optimizing spectral detection bands and scanning modalities. ImageJ software was used for data  
1301 analysis.  
1302

1303 Operetta CLS, high-throughput spinning-disk confocal microscopy system (Perkin Elmer), by Harmony  
1304 software 4.9. Cells are imaged with 20x water immersion objective NA 1.0  
1305

1306 Confocal microscopy was performed with a Leica TCS SP5 confocal laser scanning system based on a  
1307 Leica DMI 6000B inverted microscope. The images were acquired with a HCX PL APO 63X/1.4NA oil  
1308 immersion objective. The software used for all acquisitions was Leica LAS AF. Laser lines: 405nm, 488nm,  
1309 561nm, 633nm.  
1310

1311 Hypotonic-mediated cell streaming and EGFP-3NLS leakage time lapses were performed with a Leica  
1312 Thunder Imaging System based on a Leica DMI8 inverted microscope equipped with a Leica DFC9000 GT  
1313 sCMOS camera. The images were acquired with a HC PL APO 63X 1.4NA oil immersion objective (EGFP-  
1314 3NLS time lapse) using Leica LAS X software.  
1315

1316 Image acquisition of cGAS expression and localization on FFPE samples was performed with an Olympus  
1317 BX63 full motorized wide field microscope equipped with a B/W Hamamatsu Orca\_AG camera. the system  
1318 is driven by Metamorph (Molecular Devices) software. We used UPlanApo 100x objective N.A.1.35  
1319

### 1320 **Growth assay Survival and broken nuclei discrimination**

1321 To evaluate the growth of MCF10.DCIS control empty vector mCherry H2B or RAB5A mCherry H2B a  
1322 Harmony 4.9 (PerkinElmer) custom pipeline was implemented. After 3 days of treatment, the images were  
1323 acquired. For each well (four wells each condition) composed by 89 fields, the pipeline identifies the nuclei  
1324 on the gaussian filtered (radius 3 pixel) global image of mCherry channel using the B method of the Find  
1325 Nuclei module (parameters were tuned condition by condition). Then the nuclei are filtered by intensity and  
1326 morphological criteria. To discriminate broken and normal nuclei, the Linear Classifier module with 2  
1327 classes is used; the classifier was trained using around 30 nuclei both classes.  
1328

### 1329 **Image analyses**

1330 In order to count the number of Foci per Nuclei, a custom semi-automated Fiji<sup>102, 103</sup> plugin was developed.  
1331 The plugin identifies on the Dapi/Nuclear Marker using Li (<https://imagej.net/plugins/auto-threshold#li>)  
1332 Thresholding Schema on the filtered image (gaussian filter with radius 2 pixel). Nuclei are then splitting  
1333 using watershed (<https://imagej.net/plugins/classic-watershed>)method and then checked and corrected by  
1334 hand. For each nucleus, the plugin identifies and counts the foci on the Foci Channel Marker (53BP1 or  
1335 γH2AX) using the ImageJ's Find Maxima (<https://imagej.nih.gov/ij/docs/menus/process.html#find-maxima>)  
1336 plugin with the noise tolerance parameter selected by hand.  
1337

1338 In order to count the number of Foci per Field Of View (FOV), a custom semi-automated Fiji<sup>102, 103</sup> plugin  
1339 was developed. The plugin identifies on the Dapi/Nuclear Marker using Huang  
1340 (<https://imagej.net/plugins/auto-threshold#huang>). Thresholding Schema on the filtered image (median  
1341

1336 filter with radius 1 pixel). Nuclear structures were then split using watershed  
1337 (<https://imagej.net/plugins/classic-watershed>) method and then checked and corrected by hand. For each  
1338 FOV, the plugin identifies and counts micronuclear structures using ImageJ's Analyze Particles  
1339 (<https://imagej.net/imaging/particle-analysis>) plugin with the size parameters selected by hand.

1340 For assessing histone methylation on Lysine 27, fields of view were randomly selected based on nuclei  
1341 signal, probed by DAPI staining. Images were analyzed using a custom semi-automated plugin developed  
1342 in Fiji<sup>102, 103</sup>. Nuclei were identified on DAPI channel using StarDist plugin (<https://imagej.net/plugins/stardist>)  
1343 with the built-in Versatile (fluorescent nuclei) neural network model. For each nuclear region of interest, the  
1344 mean intensity was measured on the H3K27me3 channel and then normalized on the median of the mean  
1345 intensity distribution of control cells.

1346 For the analysis of the differential signal intensity at the nuclear periphery and central region, images  
1347 were acquired and nuclei were segmented as described above. For each nuclear region of interest, the  
1348 area was reduced to shrink it 1.5  $\mu$ m from the nuclear border and the mean intensity in the H3K27me3  
1349 channel was calculated in the central nuclear region. Finally, the peripheral H3K27me3 mean intensity was  
1350 calculated in the area comprised between the central region and the nuclear border.


### 1351 Cell area fluctuation analysis

1352 EGFP-E-cadherin expressing control and RAB5A-MCF10A cells were generated as described. Cells were seeded in 6-well plate (1.5\*10<sup>6</sup> cells/well) in complete medium and cultured until a uniform monolayer had  
1353 formed. RAB5A expression was induced, were indicated, 16 hours before performing the experiment by  
1354 adding fresh complete media supplemented with 2.5  $\mu$ g/ml doxycycline to cells. Comparable cell confluence  
1355 was tested by taking pictures by differential interference contrast (DIC) imaging using a 10x objective and  
1356 counting the number of nuclei/field. To monitor cell fluctuations the phase contrast channel and EGFP-E-  
1357 Cad channel were merged first and then the 2D videos were converted into 3D image stacks with x, y and  
1358 t, as shown in the scheme (a). Based on the phase contrast image and the E-Cad signal, random selected  
1359 cells are segmented and tracked semi-automatically using Segmentation Editor in Fiji (ImageJ plug-in). Cell  
1360 boundaries were annotated manually with the interval of a few time points and then cell boundaries at other  
1361 time points are interpolated in 3D to obtain accurate cell morphological dynamics along time. The  
1362 segmentation and tracking results are shown in Fig. S2b. The random pseudo-color presents the cell  
1363 identity for the visualization purpose. We can see that the cell tracking is represented as a "worm" structure  
1364 in the space of x, y and t in 3D, while the RAB5 results are curlier than the Ctrl. The cell speed is calculated  
1365 based the cell centroids and the cell area of each time points are also computed. As we have excellent  
1366 temporal resolution, we assume that any deformation along the norm direction of a cell surface is small  
1367 enough such that we can treat it as linear. Thus, we can estimate the deformation of a given cell along time.  
1368 The negative and positive cell extension of the cell, as shown in Fig. 2F, can be quantitatively extracted.  
1369 For a migrating cell, its surface can be described as a function of time, i.e. S(x, y, t). The deformation  
1370 between any two-time points is the partial differentiation of function S along t, given by:  
1371

$$\Delta S = \frac{\partial S}{\partial t} \quad \text{Eq. (1)}$$

1372 Based on our linear assumption, Eq. (1) is actually to find a linear minimum distance mapping for the points  
1373 on the boundaries at two time points.  
1374

**a**



1375 In the scheme (b), we demonstrate the cell boundaries of two consecutive points with the Maximum Positive  
1376 Deformation (MPD) and Maximum Negative Deformation (MPD). The arrows show the marching points.  
1377 We also need to define if the deformation is positive (extending) or negative (retracting). The positive  
1378

1380 deformation means a boundary-points moving to a space which is not previously occupied by this cell,  
1381 shown by the red arrows; while the negative deformation means a boundary point moving to a space which  
1382 is previously occupied by this cell, shown as the blue arrow. To quantify the cell mobility, we defined the  
1383 following 6 parameters:

1384 1. Cell Area;  
1385 2. Cell Speed;  
1386 3. Maximum Deformation: The maximum norm of the positive deformation vectors, shown as the solid  
1387 red arrow;  
1388 4. Minimum Deformation: The maximum norm of the negative deformation vectors, shown as the solid  
1389 blue arrow.

1390 **Nuclei tracking and segmentation**

1391 Tracking and segmentation of single nuclei in sequences of fluorescent microscopy images of confluent  
1392 monolayers of mCherry-H2B cells is performed *via* a custom Matlab code implementing the following  
1393 procedure.

1394 Images are first corrected for background intensity inhomogeneities by applying the background removing  
1395 algorithm described in detail in Ref.<sup>104</sup>.

1396 Random noise in each corrected image is then reduced by applying a Wiener filter<sup>104</sup>, an adaptive noise-  
1397 removal filtering that preserves nuclei edges while smoothing the white noise (see Eq. 9.44-9.46 in Ref.<sup>105</sup>).  
1398 Nuclear segmentation obtained by applying a seeded watershed transform to each filtered image<sup>106</sup>. The  
1399 “seeds” (i.e. the pixels that are set to zero in the image before applying the watershed transform) are  
1400 determined as follows. A Laplacian-of-the-Gaussian (LoG) filter is applied to each filtered image, leading to  
1401 a map  $L_G$  whose local minima correspond to the candidate centers of the nuclei. Differences in the  
1402 fluorescent intensity of different nuclei are corrected by dividing  $L_G$  by an intensity map obtained *via* bicubic  
1403 interpolation of the minima of  $L_G$ . The resulting map  $\tilde{L}_G$  is binarized by setting to zero (one) all pixels whose  
1404 value is above (below) a fixed threshold value  $k$ . Repeated pixel erosion operations are applied to the  
1405 obtained binary mask to remove smallest features and separate partially overlapping nuclei, leading to a  
1406 final binary map  $L_{BN}$  from which we extract the “seeds” to be used in the seeded watershed transform:  
1407 internal “seeds” are obtained as the pixels where  $L_{BN}$  is non-zero, while external “seeds” as obtained the  
1408 boundaries of the watershed transform of  $L_{BN}$ .

1409 Once completed the segmentation procedure on a given image, we can determine the center of mass  $\vec{x}_i$  of  
1410 each nucleus in the image, its projected area  $A_i$  and the angle  $\theta_{n,i}$  (modulo  $\pi$ ) between the major axis of  
1411 the nucleus and the  $x$  axis. The direction of the major axis is obtained as the direction of the eigenvector of  
1412 the covariance matrix of the segmented area associated with the larger eigenvalue<sup>107</sup>.

1413 To reconstruct cell trajectories, we employ the Matlab code freely available at  
1414 <http://site.physics.georgetown.edu/matlab/> implementing the algorithm developed by Crocker and  
1415 Grier<sup>108</sup>. Once nuclei in different frames are linked into trajectories, the time evolution of the relevant single-  
1416 nucleus parameters  $\vec{x}_i(t)$ ,  $A_i(t)$  and  $\theta_{n,i}(t)$  can be determined.

1417 The instantaneous velocity of the  $i$ -th nucleus at frame  $t$  is estimated as  $\vec{v}_i(t) = (\vec{x}_{i+1}(t) - \vec{x}_{i-1}(t))/2\delta t$ ,  
1418 where  $\delta t$  is the time interval between two consecutive frames. The instantaneous mean migration velocity  
1419 is computed as  $\vec{v}_{cm}(t) = \langle \vec{v}_i(t) \rangle_i$ , where  $\langle \dots \rangle_i$  denotes the average over all the nuclei in the field of view  
1420 (FOV). The amplitude of the velocity fluctuations is evaluated as the root mean square velocity of the nuclei  
1421 in the center of mass reference frame  $v_{rms}(t) = \sqrt{\langle |\vec{v}_i(t) - \vec{v}_{cm}(t)|^2 \rangle_i}$ .

1422 The velocity spatial correlation function is calculated as  $C_{vv}(r) = \langle \langle \frac{\vec{v}_i(t) \cdot \vec{v}_j(t)}{|\vec{v}_i(t)| |\vec{v}_j(t)|} \delta(|\vec{x}_i(t) - \vec{x}_j(t)| - r) \rangle_{i,j} \rangle_t$  where  $i$  and  
1423  $j$  run over all the nuclei and  $t$  is averaged over the time window 4-20 h, unless otherwise indicated. An  
1424 estimate of the correlation length  $L_c$  of the velocity field is obtained by fitting a stretched exponential model  
1425  $e^{-\left(\frac{r}{L_c}\right)^\alpha}$  to  $C_{vv}(r)$ .

1426 Visual inspection reveals that the described segmentation procedure is effective in identifying about 90-  
1427 95% of the nuclei present in the field of view. Despite the effort to reduce multiple segmentation and nuclei  
1428 merging, however, some segmentation errors occur, especially in those cases where the signal-to-noise  
1429 ratio is low or partial superpositions of nuclei is frequent. To minimize the impact of segmentation errors  
1430 on the analysis of nuclear features, we implemented a “quality filter” to remove potentially flawed  
1431 measurements. To this end, we compute the total instantaneous intensity  $J_i(t)$  integrating the image  
1432 intensity  $I(\vec{x}, t)$  over the segmented area of the  $i$ -th nucleus at frame  $t$ . We then compare the instantaneous

value  $J_i(t)$  with its median  $med[J_i(t')]$  evaluated over the previous 10 frames. If  $|med[J_i(t')] - J_i(t)| / med[J_i(t')]^{i-1}$  is larger than 0.1, the segmentation of the  $i$ -th nucleus at frame  $t$  is considered unreliable and the corresponding parameters are not included in the statistics. Trajectories which, after the application of the this “quality filter”, lose more than 20% of frames because of this procedure are entirely excluded.

### 1438 Particle image velocimetry

1439 Particle image velocimetry (PIV) of fluorescent microscopy images of confluent monolayers of mCherry-  
1440 H2B cells fluorescent images is performed by using the Matlab PIVLab software<sup>109</sup>.

1441 We choose an interrogation area with size slightly larger than the typical inter-nuclear distance, typically  
1442 corresponding to 14  $\mu\text{m}$ . Outliers in the reconstructed velocity field, whose modulus exceed a fixed  
1443 threshold value, are identified and replaced with the median value of the velocity over neighboring grid  
1444 points.

### 1445 Nuclear deformation dynamics

1446 In order to characterize nuclear shape fluctuations, we evaluate the mean square nuclear strain  $MSS(\tau) =$   
1447  $\langle (\Delta a_i)^2(\tau|t) \rangle_t$  for different delay times  $\tau$ . The nuclear strain  $\Delta a_i(\tau|t)$  is estimated as  $[A_i(t + \tau) - A_i(t)] /$   
1448  $\langle A_i(t) \rangle_t$ , where  $A_i(t)$  is projected area of the  $i$ -th nucleus at time  $t$ . To extract the key parameters  
1449 characterizing nuclear deformation, we fit the model function  $MSS(\tau) = \sigma_w + \dot{\gamma}_0 \tau_c [1 - e^{-\tau/\tau_c}]$  to the data.  
1450 This model, which includes a term  $\sigma_w$  accounting for the random noise in determination of the projected  
1451 area, describes a diffusive-like growth of the area fluctuations with a characteristic strain rate  $\dot{\gamma}_0$  for short  
1452 delay times  $MSS(\tau) \sim \dot{\gamma}_0 \tau$ , followed by a saturation to a plateau value  $\dot{\gamma}_0 \tau_c$  for long times. In figure 2G-H,  
1453 the data and the best fitting curves are reported upon the subtraction of the baseline value  $\sigma_w$  obtained  
1454 from the fitting procedure. Since the  $MSS(\tau)$  does not always reach a clear plateau within the time window  
1455 accessible during the experiments (Fig. 2G-H), there is a relatively large uncertainty in the determination of  
1456 the overall amplitude  $\dot{\gamma}_0 \tau_c$  of the fluctuations. However, this does not affect the robustness of the estimate  
1457 of  $\dot{\gamma}_0$ , as it characterizes the short time behavior of the fluctuations which is accurately sampled in our  
1458 experiments.

### 1459 Nuclei relative stiffness

1460 In order to characterize the mechanical response of cell nuclei to intracellular stresses induced by mutual  
1461 cell displacements, we evaluate independently nuclear and cell deformations by measuring the  
1462 instantaneous nuclear strain rate and the corresponding instantaneous cell strain rate.

1463 The first one is evaluated for a nucleus  $i$  at time  $t$  as  $\dot{\gamma}_n(\vec{x}_i, t) = [a_i(t + \delta t) - a_i(t)] / \delta t$ , where  $\delta t$  is the time  
1464 interval between two consecutive acquired frames and  $a_i(t) = A_i(t) / \langle A_i(t) \rangle_t$ . From the instantaneous  
1465 velocity field  $\vec{v}(\vec{x}, t)$  obtained from PIV analysis we compute the divergence  $div \vec{v}(\vec{x}, t) = \frac{\partial v_x(\vec{x}, t)}{\partial x} + \frac{\partial v_y(\vec{x}, t)}{\partial y}$ .

1466 The divergence can be used as a proxy of the local deformation state of the monolayer. Qualitatively, a  
1467 negative value of the divergence in a given position  $\vec{x}$ , indicates that cells are locally converging toward  
1468 that point, leading to local compression (see Fig. 4A). Vice versa, positive values of divergence correspond  
1469 to a local dilatation of the monolayer. In more rigorous terms, one can consider the local cell strain rate  
1470  $\dot{\gamma}_c(\vec{x}, t) \equiv \frac{1}{A_c(\vec{x}, t)} \frac{\partial A_c(\vec{x}, t)}{\partial t}$ , where  $A_c(\vec{x}, t)$  is the cell area, i.e. the inverse of the local cell number density  $\rho(\vec{x}, t)$ .

1471 By using the continuity equation  $div \vec{v} \rho = -\frac{\partial \rho}{\partial t}$ , under the hypothesis of small density fluctuations, one gets  
1472  $\dot{\gamma}_c(\vec{x}, t) \cong div \vec{v}(\vec{x}, t)$ . This identity suggests that the mean square value of the divergence of the velocity  
1473 field can be used to estimate the characteristic strain amplitude associated to monolayers internal  
1474 deformations.

1475 For every segmented nucleus  $i$  and time  $t$ , we consider the pair of values  $[\dot{\gamma}_c(\vec{x}_i, t), \dot{\gamma}_n(\vec{x}_i, t)]$  obtained by  
1476 associating the instantaneous nuclear strain rate  $\dot{\gamma}_n(\vec{x}_i, t)$  with the corresponding cell strain rate  $\dot{\gamma}_c(\vec{x}_i, t)$  in  
1477 the position  $\vec{x}_i(t)$ , in the position  $\vec{x}_i(t)$ , estimated by bicubic interpolation of  $div \vec{v}(\vec{x}, t)$ . The data are shown  
1478 in the scatter plot of Figure 4D-E after grouping into evenly spaced bins along the horizontal axis. In all  
1479 investigated cases, we find a significant linear correlation between the two strain rates. Fitting a linear  
1480 homogenous model to the data  $\dot{\gamma}_n = s \cdot \dot{\gamma}_c$  enable estimating the dimensionless parameter  $s$  characterizing  
1481 the relative deformation of a whole cell and the one of its nucleus. If we assume a minimalistic mechanical  
1482 model, where the nucleus and the outer part of the cell are represented by two linear elements (whose  
1483 deformation -or deformation rate- is proportional to the applied stress via a characteristic mechanical  
1484 modulus) in series, our experimental findings enable interpreting the ratio  $1/s$  between nuclear and whole  
1485 cell strain rate as the ratio between the corresponding mechanical moduli or, in other terms, as the stiffness  
1486

1487 of the nucleus normalized by the average stiffness of the whole cell. We note that, while the term "stiffness"  
1488 may make think of an elastic-like response, we are not assuming here any specific model for the cell or the  
1489 nuclear rheology. As a matter of fact, since the characteristic time scale of the considered fluctuations is  
1490 very short and close to the inverse of the sampling frequency, in our experiments we are not able to  
1491 accurately characterize the relative phase of nuclear and cellular deformation and thus to distinguish  
1492 between a more liquid-like and a solid-like response.

#### 1494 **Nuclear MSAD and velocity-orientation correlation**

1495 We measure the nuclear rotational dynamics through the analysis of the orientations  $\theta_{n,i}(t)$  of the nuclei  
1496 and of the direction of the instantaneous velocity  $\theta_{v,i}(t)$ , both obtained from PT.

1497 The overall mean square angular displacement  $MSAD(\tau)$  at a given time delay  $\tau$  is evaluated averaging the  
1498 single nuclei mean square angular displacements as  $MSAD(\tau) = \langle \langle \Delta\theta_{n,i}^2(\tau|t) \rangle_t \rangle_i$  (Fig. S6D). We then fit  
1499 the  $MSAD$  with a ballistic-diffusive model  $MSAD(\tau) = \sigma_{wr} + D_r \left[ \tau + \frac{D_r}{\omega} (e^{-\tau\omega^2/D_r} - 1) \right]$ , where  $D_r$  and  $\omega$  are  
1500 the rotational diffusion coefficient and the ballistic angular velocity, respectively. The term  $\sigma_{wr}$  is introduced  
1501 to account for the random noise due to the segmentation errors. In Fig. S6D, the data and the best fit are  
1502 reported upon the subtraction of the fitted  $\sigma_{wr}$ .

1503 In order to evaluate the degree of correlation between nuclear orientation and velocity we also considered  
1504 the distribution of the angular difference  $\Delta\theta_i(t) = \theta_{n,i}(t) - \theta_{v,i}(t)$ , which is reported in Figure 6E as a polar  
1505 plot. Absence of correlation corresponds to a uniform distribution of  $\Delta\theta$ . Conversely, the presence of a peak  
1506 in the distribution for  $\Delta\theta = 0$  indicates a tendency of the cell major axis of the nucleus to be oriented along  
1507 the direction of cell velocity.

#### 1508 **Immunostaining**

1509 As previously described<sup>1</sup>, cells were washed twice with 1X PBS, fixed in 4% paraformaldehyde for 10 min  
1510 and permeabilized with 0.1% Triton X-100 and 10% FBS for 10 min. After a 1X PBS wash, primary  
1511 antibodies were added for 2 h at room temperature. Coverslips were washed in 1X PBS before secondary  
1512 antibody incubation for 1 h at room temperature, protected from light. FITC-phalloidin was added in the  
1513 secondary antibody step, where applicable. After removal of not specifically bound antibodies by 1X PBS  
1514 washing, nuclei were stained with 0.5 ng ml<sup>-1</sup> DAPI. Samples were post-fixed and mounted on glass slides  
1515 in anti-fade mounting medium (glycerol). Antibodies were diluted in 1X PBS and 10% FBS.

#### 1517 **Electron microscopy**

1518 Electron microscopic examination, immune EM gold labelling based on pre-  
1519 embedding, EM tomography and correlative light-electron microscopy (CLEM) were performed as  
1520 previously described<sup>110-112</sup>. A brief description of each process is presented below.

1521 Embedding: Cells grown on MatTek glass bottom dishes (MatTek Corporation, USA) were fixed with  
1522 4% paraformaldehyde and 2,5% glutaraldehyde (EMS, USA) mixture in 0.1 M sodium cacodylate pH 7.4  
1523 for 2 h at RT, followed by 6 washes in 0.2 sodium cacodylate pH 7.2 at RT. Then cells were incubated in  
1524 the 1:1 mixture of 2% osmium tetroxide (OsO<sub>4</sub>) and 3% potassium ferrocyanide for 1 h at RT followed  
1525 by 6 times rinsing in cacodylate buffer. Further, the samples were sequentially treated with 0.3%  
1526 Thiocarbohydrazide in 0.2 M cacodylate buffer for 10 min and 1% OsO<sub>4</sub> in 0.2 M cacodylate buffer (pH  
1527 6,9) for 30 min. Next, samples were rinsed with 0.1 M sodium cacodylate (pH 6.9) buffer until all traces  
1528 of the yellow osmium fixative have been removed<sup>16</sup>. The samples were subsequently subjected to  
1529 dehydratation in ethanol, embedded in Epoxy resin at RT, and polymerized for at least 72 h in a 60 °C oven.

1530 ImmunoEM. Gold Enhancement: Cells grown on MatTeks were fixed with a mixture of 4%  
1531 paraformaldehyde and 0.05% glutaraldehyde in 0.15M Hepes for 5 min at RT and then replaced with 4%  
1532 paraformaldehyde in 0.15M Hepes for 30 min. Afterwards, the cells were washed 3 times in PBS and  
1533 incubated with blocking solution for 30 min at RT. Then cells were incubated with primary anti GFP antibody  
1534 (Abcam ab6556) a diluted 1:100 in blocking solution overnight at 4°C. On the following day, the cells  
1535 were washed 3 times with PBS and incubated with goat anti-rabbit Fab' fragments coupled to 1.4nm gold particles (diluted in blocking solution 1:100) for 2h and  
1536 washed 6 times with PBS. Meanwhile, the activated Gold Enhance TM-EM was prepared according to the  
1537 manufacturer's instructions and 200  $\mu$ l were added into each sample well. The reaction was  
1538 monitored by a conventional light microscope and was stopped after 5-10 min when the cells had turned  
1539 "dark enough" by washing several times with PBS. Then cells were fixed with of 2,5 % paraformaldehyde  
1540 and 2,5% glutaraldehyde (EMS, USA) mixture in 0.1 M sodium cacodylate pH 7.4 for 2 h at RT, followed  
1541 by 6 times rinsing in cacodylate buffer. Finally, the samples were post-fixed with 1% OsO<sub>4</sub> in 0.2 M  
1542 cacodylate buffer (pH 6.9) for 30 min and rinsed with 0.1 M sodium cacodylate (pH 6.9) buffer until all traces  
1543 of the yellow osmium fixative have been removed<sup>16</sup>.

1543 by 6 washes in 0.1 sodium cacodylate pH 7.4 at RT. Then cells were incubated in 1:1 mixture of 2%  
1544 osmium tetra oxide and 3% potassium ferrocyanide for 1 h at RT followed by 6 times rinsing in cacodylate  
1545 buffer. Then the samples were sequentially treated with 0.3% Thiocarbohydrazide in 0.2 M cacodylate  
1546 buffer for 10 min and 1% OsO<sub>4</sub> in 0.2 M cacodylate buffer (pH 6,9) for 30 min. The samples were  
1547 subsequently subjected to dehydration in ethanol, and embedded in Epoxy resin at RT and polymerized  
1548 for at least 72 h in a 60 °C oven<sup>111</sup>.

1549 **Sectioning:** The cell of interest was selected during the analysis of the MatTek and then this cell was  
1550 subjected to the optical sectioning and the Z-stacking was performed using confocal microscope. Then, the  
1551 sample was subjected to the procedure of immune EM labelling with an antibody against the defined  
1552 proteins (antigens) using the Nanogold enhancement procedure as it was described<sup>111, 112</sup>. Z-stack images  
1553 were printed and during trimming of the pyramid and its sharpening these images were constantly used for  
1554 orientation. Embedded samples were then sectioned with diamond knife (Diatome, Switzerland) using Leica  
1555 EM UC7 ultra microtome. Sections were analyzed with a Tecnai 20 High Voltage EM (FEI, Thermo  
1556 Fisher Scientific; The Netherlands) operating at 200 kV.

1557 **EM Tomography:** Two-step CLEM based on the analysis of tomographic reconstructions acquired under  
1558 low magnification with consecutive reacquisition of EM tomo box under high magnification and its re-  
1559 examination was used exactly as described<sup>111</sup>. Briefly, an ultramicrotome (Leica EM UC7; Leica  
1560 Microsystems, Vienna) was used to cut 200 nm serial semi-  
1561 thick sections. Sections were collected onto 1 % Formvar films adhered to slot grids. Both sides of the  
1562 grids were labelled with fiduciary 10 nm gold (PAG10, CMC, Utrecht, the Netherlands). Tilt-  
1563 series were collected from the samples from ± 65° with 1° increments at 200 kV in Tecnai 20 electron  
1564 microscopes (FEI, Thermo Fisher Scientific, Eindhoven, the Netherlands). Tilt series were  
1565 recorded at a magnification of 9,600x, using software supplied with the instrument. The nominal  
1566 resolution in our tomograms was 4 nm, based upon section thickness, the number of tilts, tilt increments,  
1567 and tilt angle range. The IMOD package and its newest viewer, 3DMOD 4.0.11, were used to construct  
1568 individual tomograms and for the assignment of the outer leaflet of organelle membrane contours,  
1569 CLEM was performed exactly as described<sup>110</sup>.


### 1570 1571 **Statistical analysis**

1572 All data are presented as scatter plots or box plots expressed as mean ± standard deviation (s.d.) unless  
1573 otherwise indicated. The number of experiments as well as the number of samples analyzed is specified  
1574 for each experiment and reported in the figure legends. Statistical significance was calculated, whenever  
1575 we compared two distinct distributions, using a parametric two-tails unpaired student's t-test with Welch  
1576 corrections for two samples with un-equal variance or non-parametric two-tails Mann-Whitney t-test as  
1577 indicated. Nested one-way ANOVA was used as reported for comparison of more unmatched groups.  
1578 Significance was defined as \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001 and \*\*\*\*p < 0.0001. Statistical calculations  
1579 were performed with GraphPad Prism 8 Software or Microsoft Excel software.

1580  
1581

1582

Figure S1



1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603


**Figure S1. Tissue fluidification induces a CytoDR gene signature in MCF10 monolayers and has marginal effect on Interferon and Interferon receptor genes**

**A.** Volcano plot representing differentially expressed genes between control empty vector and RAB5A-expressing MCF10A monolayers. All significantly RAB5A-expressing deregulated genes are indicated in red (upregulated) and blue (downregulated). The enrichment (log2Fold Change) is plotted on the x-axis and the significance (Wald test -log10 p value) is plotted on the y-axis. Labels show genes validated in Fig. 1D.

**B.** Gene set enrichment analysis (GSEA) of differentially expressed genes in RAB5A-expressing MCF10A monolayer over control cells. GSEA was performed using the Hallmarks pathway gene sets in the GSEA Molecular Signatures Database. Moderated t-statistic was used to rank the genes. Reported are significantly enriched pathways ( $P\text{-value} < 0.05$ ) with the color of the outline of the bar corresponding to the BH-adjusted  $P\text{-value}$ .  $P\text{-value}$  was calculated as the number of random genes with the same or more extreme ES value divided by the total number of generated gene sets.

**C.** Immunoblots of lysates from doxycycline-treated control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com monolayers with the indicated antibodies. Mw are indicated on the left.

**D.** Heatmap showing the relative expression of interferon and interferon receptor genes in each of the 3 replicates of the conditions control empty vector (EV) and RAB5A-expressing (RAB5A) respectively in MCF10.DCIS and MCF10A monolayers.



1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635

**Figure S2. Tissues fluidification induces CytoDR gene expression in various normal and tumoral epithelia**

**A.** Scatter plots of the mRNA expression levels of IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT3, ISG15, OASL and RAB5A determined by qRT-PCR in different RAB5A-expressing cell lines over the respective control cells (3D MCF10.DCIS.com spheroids, SUM-225 and 4T1monolayers). Data are the mean (at least  $n=2$  independent experiments). Values were normalized to the controls in each experiment.

**B.** Scatter plots of the mRNA expression levels of RAB5A, IFI44, IFI44L, IFI27, IFI6, IFIT1, IFIT3, ISG15 and OASL determined by qRT-PCR in doxycycline-treated RAB5A-expressing MCF10.DCIS.com monolayers or sparsely seeded cells (sparse) over the corresponding control cells. Data are the mean  $\pm$  s.d. ( $n=3$  independent experiments). Values were normalized to the controls of each experiment.


**C.** Scatter plots mRNA expression levels of IFI6, IFIT1, ISG15 and OASL determined by qRT-PCR in MCF10.DCIS.com cells incubated with hypotonic medium at the indicated time points. Data are expressed as mean ( $n = 3$  independent experiments). Values were normalized to the controls of each experiment.

**D.** Migration parameters of control (CTR) or RAB5A-expressing (RAB5A) MCF10.DCIS.com monolayers treated with hypotonic media for 48 h (see Movie S1), obtained from PIV analysis. Left panel: migration speed  $v_m$ . Central panel: spatial velocity correlation functions  $C_{vv}$  evaluated over the time window 8-40 h. In the inset are reported the corresponding correlation lengths  $L_c$  obtained from stretched exponential fits on  $C_{vv}$  curves (black dashed lines in the main panel). Right panel: root mean square velocities in the center of mass reference frame. Velocity fields are computed over 4 FOVs per condition (each FOV including more than  $2 \cdot 10^3$  cells). The width of each of the shaded regions reported in the left and in the right panel corresponds to 2 times the standard deviation of the corresponding variable, evaluated over different FOVs.

**E.** Scatter plots of the mRNA expression levels of IFI27, IFI44, IFI44L, IFI6, IFIT1, IFIT3, ISG15, OASL and RAB5A determined by qRT-PCR in MCF10.DCIS.com monolayers subjected to different conditions (doxycycline-induction of RAB5A-expression, hypotonic treatment or the combination of both) over control cells. Data are the mean ( $n = 2$  independent experiments). Values were normalized to the controls of each experiment.

**F.** Immunoblots with the indicated antibodies from doxycycline-treated lysate of control (CTR) and RAB5A-expressing (RAB5A) monolayers or from hypotonic treated cells at the indicated time points. Mw are indicated on the left.





1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667

**Figure S3. Tissue fluidification-dependent CytoDR is mediated by RAB5A in MCF10.DCIS.com and HaCat.**


**A.** Heatmap representing color-coded expression levels of differentially expressed CytoDR genes in RAB5A-expressing MCF10.DCIS.com monolayer treated as indicated. The data are the ratio of relative level of gene expression compared to RAB5A-expressing cells expressed as mean  $\pm$  s.d. (at least  $n = 3$  independent experiments). P values, each-pair Student's t-test (treated versus RAB5A-expressing cells) are reported in Table Figure S3A.

**B.** Scatter plot of the mRNA expression levels of IFI44L, IFI6, IFIT1, ISG15 and OASL (left panel) determined by qRT-PCR in MCF10.DCIS.com monolayer expressing RAB5A, RAB5B or RAB5C (right panel) over control cells. Data are expressed as mean (at least  $n = 3$  independent experiments). Values were normalized to the controls of each experiment.

**C-E.** Migration parameters of HaCat monolayers, obtained from nuclear tracking. Doxycycline-treated control or RAB5-expressing HaCat monolayers were serum starved (SS) for 48 h before addition of 100 ng/ml of EGF and monitored by time lapse microscopy (see Movie S2). **(C)** Migration speed  $v_m$ . **(D)** Spatial velocity correlation functions  $C_{vv}$  evaluated over the time window 8-40 h. In the inset we report the corresponding correlation lengths  $L_c$  obtained from stretched exponential fits on  $C_{vv}$  curves (black dashed lines in the main panel). **(E)** Root mean square velocities in the center of mass reference frame. Velocity fields are computed over different FOVs, encompassing in total about  $10^4$  tracked cells per frame per condition. The width of each of the shaded regions reported in the left and in the right panel corresponds to 2 times the standard deviation of the corresponding variable, evaluated over different FOVs.

**F.** Box plot of the mRNA expression levels of RAB5A, IFI6, IFI27, IFI44, IFIT1, IFIT3, ISG15 and OASL determined by qRT-PCR in doxycycline-treated control (CTR) and RAB5A-expressing HaCat monolayers treated exactly as described above with respect to control cells. Monolayers were serum starved mock treated or stimulated with 100 ng/ml EGF: Hatched blue bar, serum starved HaCat CTR + EGF; Red bars, HaCat RAB5A- serum starved; hatched red bar, serum starved HaCat RAB5A stimulated with 100 ng/ml EGF (Serum Starved HaCat RAB5A = EGF) over control serum starved HaCat cells. Data are expressed as mean  $\pm$  s.d. (at least  $n = 3$  independent experiments). Values were normalized to the controls of each experiment.

Figure S4



1671

1672

1673 **Figure S4. Tissue fluidification activates the mechano-transducer YAP1**

1674 A. Box plot of the mRNA expression levels of cGAS, STING, IRF3, IRF9, STAT1 and STAT2 determined  
1675 by qRT-PCR in RAB5A-expressing MCF10.DCIS.com monolayer over control cells silenced with indicated  
1676 oligos. Data are expressed as mean  $\pm$  s.d. (at least  $n=3$  independent experiments). Values were  
1677 normalized to the controls of each experiment.

1678 B. Number of micronuclei per field of view (FOV) in control (CTR) and RAB5A-expressing  
1679 MCF10.DCIS.com monolayers is expressed as the mean  $\pm$  s.d. (at least  $n=100$  FOV/experimental  
1680 conditions in three independent experiments). ns>0.999, P values, each-pair Mann Whitney test (CTR  
1681 versus RAB5A).

1682 C. Immunofluorescence images of control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com  
1683 monolayers stained with Dapi and anti-YAP antibody to detect nuclei and YAP localization, respectively.  
1684 Scale bar 40  $\mu$ m.

1685 D. Scatter plot of the percentage of cells with nuclear YAP is expressed as the mean  $\pm$  s.d. (at least  $n=5$   
1686 FOV/experimental conditions in three independent experiments). \*\*\*\*p < 0.0001, P values, each-pair  
1687 Welch's test (CTR versus RAB5A).


1688 E. Scatter plot of the mRNA expression levels of CTGF, CYR61, ANKRD1 and RAB5A determined by qRT-  
1689 PCR in RAB5A-expressing MCF10.DCIS.com monolayers over control cells. Data are from at least 3  
1690 independent experiments. Values were normalized to the controls of each experiment.

1691 F. Immunofluorescence images of control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com  
1692 injected into mammary fat pads of immunocompromised mice. After four weeks, primary tumors were  
1693 isolated, sectioned and cultivated as organotypic tumor slices for 6 days at air-liquid interface over  
1694 a synthetic membrane. After adding doxycycline to induce RAB5A expression, the slices were fixed and  
1695 stained with Dapi and YAP to detect nuclei and YAP localization, respectively. Scale bar 100  $\mu$ m.

1696 G. Scatter plot of the percentage of cells with nuclear YAP is expressed as the mean  $\pm$  s.d. (at least  $n=4$   
1697 FOV/experimental conditions in three independent experiments). \*\*\*\*p < 0.0001, P values, each-pair  
1698 Welch's test (CTR versus RAB5A).

1699

Figure S5




**Figure S5. cGAS accumulation at nuclear envelope ruptures**

A. Schematic overview of experimental procedures for NE laser ablation (left panel). Snapshot of stable EGFP-cGAS/mcherry-H2B MCF10.DCIS.com monolayers (right panel). Magnified images from the selected boxed area are shown. Scale bar 20  $\mu$ m.

B. Sequential Z axis sections of EGFP-cGAS-expressing RAB5A-MCF10.DCIS.com monolayers used for 3D tomographic reconstruction shown in Figure 3F (lower right image). The image outlined in red correspond the one shown in Figure 3F (upper right image). Scale Bar, 500 nm.

1709  
1710 **C.** Immunofluorescence images of control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com  
1711 monolayers transiently transfected with EGFP-cGAS and stained with Dapi and anti-Lamin A/C antibody to  
1712 detect nuclei and nuclear lamina, respectively. Magnified images of the selected boxed area are shown.  
1713 Scale bar 20  $\mu$ m.

Figure S6



**Figure S6. Fluidized MCF10.DCIS.com monolayers display an increase nuclear size and enrichment in PRC2-targets**

1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731

**A.** Immunofluorescence images of control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com monolayers stained with Dapi to detect nuclei. Scale bar 20  $\mu\text{m}$ .

**B.** Scatter Plot of the nuclear area per field of view is expressed as the mean  $\pm$  s.d. (at least  $n = 100$  FOV/experimental conditions in three independent experiments). \*\*\* $p < 0.0001$ , P values, each-pair Mann Whitney test (CTR versus RAB5A).

**C.** Heatmap representing color-coded expression levels of differentially expressed CytoDR genes in RAB5A-expressing MCF10.DCIS.com monolayers treated with vehicle or with MK-886 that inhibits 5-lipoxygenase-activating protein (FLAP) and COX-1<sup>113</sup> or Blebbistatin. The data are the ratio between the level of gene expression in each of the conditions tested relative to those of vehicle-treated RAB5A-expressing cells expressed. The mean  $\pm$  s.d. (at least  $n = 3$  independent experiments) and P values, each-pair Student's t-test (treated versus RAB5A-expressing cells) are reported in Table Figure S6E.


**D.** Transcription factor enrichment analysis for overlap between the input set of differentially expressed genes in MCF10.DCIS.com monolayer over control cells and entries of the ChEA and ENCODE databases. Reported in the bars is the P-value (combination of Fisher's exact test and deviation from expected rank

1732 for random input gene-set). Bars are colored according to the transcription factor/target-gene interactions  
1733 from ChIP-seq/chip experiments database where they have been found enriched.

1734 **E.** GSEA Enrichment plot of the PRC2 targets gene set in the CGP collection of the GSEA Molecular  
1735 Signatures Database using differentially expressed genes in RAB5A-expressing MCF10.DCIS.com  
1736 monolayer. The green curve corresponds to the ES (enrichment score) curve, which is the running sum of  
1737 the weighted enrichment score obtained from GSEA software, while the normalized enrichment score  
1738 (NES) and the corresponding P-value are reported within the graph.

1739 **F-G.** Box plot of the mRNA expression levels of EZH2 and SUZ12 determined by qRT-PCR in RAB5A-  
1740 expressing MCF10.DCIS.com monolayer over control cells silenced with the indicated oligos. Data are the  
1741 mean  $\pm$  s.d. (n = 3 independent experiments). Values were normalized to the controls of each experiment.

1742



1744  
1745 **Figure S7. Tissues fluidification promotes nuclear rotation, H3K9me3 reorganization and**  
1746 **perinuclear actin remodeling**

1747 A. Nuclear mean square angular displacement (MSAD) in MCF10A and MCF10.DCIS.com monolayer,  
1748 comparing control and RAB5A-expressing cells. In each condition, the MSAD is obtained by tracking and  
1749 segmenting  $n$  nuclei over the time window 4-20 h ( $n > 5000$  and  $n > 1000$  for control and RAB5A-expressing  
1750 MCF10A monolayers, respectively;  $n > 700$  and  $n > 400$  for control and RAB5A-expressing MCF10.DCIS.com  
1751 monolayers, respectively). Insets: corresponding diffusion rate  $D_\theta$  and angular velocity  $\omega$  obtained by fitting  
1752 the MSAD curves with a model function (continuous lines in the main panels) describing the transition from  
1753 a short-time ballistic to a long-time diffusive behavior. Results are the mean  $\pm$  s.d. ( $n$ = randomly populated  
1754 subsets of cells). \*\*\*p < 0.0001, P values, T test (CTR versus RAB5A).

1755 B. Polar histograms representing the probability distribution functions (PDFs) of the angle between cell  
1756 velocity (estimated from nuclear tracking) and direction of the major axis of its nucleus. Dashed black lines  
1757 represent the uniform distribution, corresponding to a complete absence of correlation between cell velocity  
1758 and nuclear orientation.

1759 C. Visual representation of genomic tracks for ChIP-seq signal enrichment and SAMMY-seq fractions  
1760 comparison for a representative chromosome (chr 16). For each position along the chromosome (x axis)  
1761 the enrichment signal (y axis) is reported as the normalized log2 ratio of ChIP over input control samples  
1762 sequencing reads for ChIP-seq and the normalized log2 ratio of S4 over S3 sequencing (S4/S3) for  
1763 SAMMY-seq. The data shown in the genomic tracks (from top to bottom) are: three SAMMY-seq replicates  
1764 on CTR and RAB5A samples; two H3K9me3 ChIP-seq replicates (performed with two alternative antibodies  
- see methods) on CTR and RAB5A.

1765 D. Average SAMMY-seq enrichment signal over heterochromatic regions (metaprofile). SAMMY-seq  
1766 experiment profiles computed on CTR and on RAB5A over-expression samples are reported (three  
1767 replicates for each condition depicted with lines of different colors - see color legend). The heterochromatic  
1768 regions were selected based on H3K9me3 ChIP-seq (with ab-176916-Abcam antibody) enriched domains  
1769 ( $n=78$  domains). The x-axis reports the relative position with respect to the start and end borders of the  
1770 considered domains (domain bodies rescaled) in addition to 1Mb flanking regions with absolute (unscaled)  
1771 coordinates. The y-axis reports the average SAMMY-seq enrichment across all the considered domains.  
1772 Similar results are obtained by considering either the S4/S2 or the S4/S3 SAMMY-seq fractions  
1773 comparisons (log2 ratios) to highlight the location of the less accessible and soluble chromatin fraction.


1774 E. Immunofluorescence images of a time course analysis in control (CTR) and RAB5A-expressing (RAB5A)  
1775 MCF10.DCIS.com monolayers stimulated with doxycycline to induce RAB5A expression, fixed at indicated  
1776 time points and stained with phalloidin to detect F-actin. Scale bar 30  $\mu$ m.

1777 F. Images of control (CTR) and RAB5A-expressing (RAB5A) MCF10.DCIS.com monolayers treated with  
1778 w/o Latrunculin and stained with the Dapi and Phalloidin to detect nuclei and F-actin respectively. Scale  
1779 bar, 20  $\mu$ m.

1780 G. Heatmap representing color-coded expression levels of differentially expressed CytoDR genes in  
1781 RAB5A-expressing MCF10.DCIS.com monolayer treated as indicated. The data are the ratio between the  
1782 level of gene expression in each of the conditions tested relative to those of mock-treated RAB5A-  
1783 expressing cells. The mean  $\pm$  s.d. (at least  $n = 3$  independent experiments) and P values, each-pair  
1784 Student's t-test (treated versus RAB5A-expressing cells) are reported in Table Figure S7E.

1786

Figure S8



**Figure S8. CytoDR genes are induced in RAB5A-expressing MCF10.DCIS.com tumor xenograft and validation of anti-cGAS antibody**


1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804

**A.** Scatter plot of the mRNA expression levels of IFI27, IFI44, IFI44L, IFI6, OASL and RAB5A determined by qRT-PCR in RAB5A-expressing MCF10.DCIS.com over control cells injected into mammary fat pads of immunocompromised mice. After one week, mice were fed with doxycycline to induce RAB5A expression and the primary tumors were isolated four weeks after doxycycline treatment, lysed and processed for total RNA extraction. Data are the mean ( $n = 2$  independent experiments). Values were normalized to the controls of each experiment.

**B.** IHC validation of the of cGAS antibodies using control (CTR) and cGAS silenced MCF10.DCIS.com cells. After silencing, cells were pelleted, included in agarose gel and fixed. Samples were embedded in paraffin, processed and stained with cGAS antibody.

**C.** Box plot of the mRNA levels of cGAS determined by qRT-PCR in MCF10.DCIS.com monolayer over control cells silenced with the indicated oligo. Data are expressed as mean  $\pm$  s.d. ( $n = 3$  independent experiments). Values were normalized to the controls of each experiment.

Figure S9



1807  
1808 **Figure S9. IHC characterization of RAB5A, pChk1 and cGAS in human DCIS and breast cancer**  
1809 **organoids**

1810 **A.** Representative (1 out of more than 20 tested) multiplex immunohistochemistry/immunofluorescence  
1811 (mIHC/IF) of RAB5A, pCHK1 and Dapi in human Ductal breast Carcinoma *in Situ* (DCIS). A magnified  
1812 image from the selected yellow boxes is shown. Scale bar 250  $\mu$ m.

1813 **B.** Representative multiplex OPAL immunohistochemistry/immunofluorescence (mIHC/IF) of cGAS and  
1814  $\gamma$ H2AX in two distinct human DCIS. Scale bar 100  $\mu$ m.


1815 **C.** Representative immunohistochemistry analysis of cGAS in human DCIS with invasive buds. A magnified  
1816 image from the selected boxed area is shown. Red Arrow indicate the crescent-like, perinuclear  
1817 accumulation of cGAS signal. Scale bar 80  $\mu$ m.

1818 **D.** Representative immunohistochemistry analysis of cGAS in locally invasive human DCIS. Magnified  
1819 images from the selected boxed area are shown. Red arrow indicates the crescent-like, perinuclear  
1820 accumulation of cGAS signal, black arrows indicate the perinuclear dotted distribution of cGAS. Scale bar  
1821 40  $\mu$ m.

1822 **E.** Representative multiplex immunohistochemistry/Immunofluorescence (mIHC/IF) of RAB5A,  $\gamma$ H2AX,  
1823 cGAS and Dapi in patient-derived breast cancer organoids. Magnified images from the selected yellow  
1824 boxes are shown. Scale bar 150  $\mu$ m.

1825  
1826

Figure S10



1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863

**Figure S10. Human breast cancer organoids that persistently rotate display elevated RAB5A, and enrichment in ISG and PRC2-dependent genes**

**A.** 3D rendering of 5 living breast cancer organoids. The size of each box along the x- and y-directions corresponds to 200  $\mu$ m.

**B.** Thin blue, orange and yellow curves: temporal evolution of the x, y and z components of the angular velocity associated with the rotation of the organoid depicted in the box above each panel, respectively. Thick black curves represent the angular speed, *i.e.*, the modulus of the angular velocity. Organoids are categorized as “rotating” if their average angular speed is larger than 0.03 cycles/h, as “non rotating” otherwise.

**C.** Symbols: overlap parameter  $Q(\tau)$  obtained from 3D-DVA analysis, capturing the internal rearrangement dynamics of the organoid depicted in the box above each panel. Continuous thin lines are best fitting curves to the data with an exponential model  $Q(\tau) = e^{-\tau/\tau^*}$ . Vertical thick lines are drawn in correspondence with the characteristic relaxation time  $\tau^*$  obtained from the fitting model.

**D.** Boxplot of the expression levels of Rab5A isoform in rotating (red) and non-rotating (blue) organoids.

**E.** Heatmap showing the top 100 deregulated genes (top 50 up and top 50 down) in each of the 3 replicates of the rotating and non-rotating organoids.


**F.** Gene set enrichment analysis (GSEA) of differentially expressed genes in rotating *versus* non-rotating organoids. GSEA was performed using the Hallmarks pathway gene sets in the GSEA Molecular Signatures Database. Moderated t-statistic was used to rank the genes. Reported are significantly enriched pathways (P-value < 0.05; number of random genes with the same or more extreme ES value divided by the total number of generated gene sets) with the color of the outline of the bar corresponding to the BH-adjusted P-value.

**G.** GSEA Enrichment plot of differentially expressed genes in rotating *versus* non-rotating organoids using the Hallmarks cytosolic DNA sensing pathway in the GSEA Molecular Signatures Database. The green curve corresponds to the ES (enrichment score) curve, which is the running sum of the weighted enrichment score obtained from GSEA software, while the normalized enrichment score (NES) and the corresponding P-value are reported within the graph.

**H.** Quantitative changes in the expression of the INF-related DNA damage resistance signature genes in rotating *versus* non-rotating organoids. The log2Fold Change is plotted on the x-axis and the significance (Wald test p value) is defined by the color code of the outline.

**I.** Transcription factor enrichment analysis for overlap between the input set of differentially expressed genes in rotating *versus* non-rotating organoids and entries of the ChEA and ENCODE databases. Reported in the bars is the P-value (combination of Fisher's exact test and deviation from expected rank for random input gene-set).

Figure S11



**Figure S11. RAB5A induction of selected mesenchymal gene is YAP1/TAZ-dependent in fluidized MCF10.DCIS.com monolayers**

A. Heatmap representing color-coded expression levels of differentially expressed EMT genes in RAB5A-expressing MCF10.DCIS.com monolayers simultaneously silenced for YAP and TAZ. The data are the ratio between the level of gene expression in each of the conditions tested relative to those of mock-treated (using scramble oligos) RAB5A-expressing cells. The mean  $\pm$  s.d. (at least n = 3 independent experiments) and P values, each-pair Student's t-test (siRNA versus RAB5A-expressing cells) are reported in [Table Figure S10A](#).

B. Box plot of the mRNA expression levels of YAP and TAZ determined by qRT-PCR in RAB5A-expressing MCF10.DCIS.com monolayer over control cells silenced with the indicated oligos. Data are expressed as mean  $\pm$  s.d. (n = 3 independent experiments). Values were normalized to the controls of each experiment.

1879

**Tables S1 to S7-Raw data and statistics of the value used in the heatmaps**

1880

**Table S1.**

1881

1882 Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. 2A and statistics.  
1883 In yellow are the relative expression levels of differentially expressed CytoDR genes in RAB5A-  
1884 MCF10.DCIS.com monolayers silenced for the indicated genes with respect to monolayers treated with  
scrambled oligos. In orange, are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+scrambled oligos	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	Values of the heatmap reported in Fig 2A.
RAB5A + siRNA cGAS	0.29	0.13	0.11	0.18	0.15	0.18	0.13	0.26	Data are expressed as mean of the independent experiments reported below
RAB5 + siRNA STING	0.15	0.20	0.09	0.29	0.20	0.21	0.11	0.15	
RAB5A + siRNA IRF3	0.32	0.16	0.15	0.17	0.13	0.16	0.11	0.12	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental conditions
RAB5A+scrambled oligos	1	1	1	1	1	1	1	1	
RAB5A + siRNA cGAS_1	0.42	0.26	0.19	0.42	0.38	0.47	0.22	0.63	
RAB5A + siRNA cGAS_2	0.08	0.09	0.06	0.05	0.03	0.03	0.06	0.05	
RAB5A + siRNA cGAS_3	0.36	0.05	0.07	0.07	0.04	0.04	0.11	0.11	
mean	0.286666667	0.133333333	0.106666667	0.18	0.15	0.18	0.13	0.263333333	
st dev	0.181475435	0.111504858	0.072341781	0.20808652	0.199248588	0.251197134	0.081853528	0.318956632	
t-test	0.002432164	0.000176143	2.82559E-05	0.002409363	0.001788796	0.004821337	5.12259E-05	0.016125146	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+scrambled oligos	1	1	1	1	1	1	1	1	
RAB5 + siRNA STING_1				0.66	0.28		0.17	0.23	
RAB5 + siRNA STING_2	0.22	0.4	0.25	0.42	0.38	0.44	0.18	0.33	
RAB5 + siRNA STING_3	0.23				0.29	0.37	0.15	0.08	
RAB5 + siRNA STING_4	0.07	0.15	0.02	0.06	0.03	0.02	0.03	0.08	
RAB5 + siRNA STING_5	0.06	0.06	0.01	0.01	0.01	0.01	0.01	0.02	
mean	0.145	0.203333333	0.093333333	0.2875	0.198	0.21	0.108	0.148	
st dev	0.092556289	0.178162803	0.135769412	0.308261253	0.167242339	0.227009545	0.081363382	0.127945301	
t-test	1.62141E-06	0.001434444	0.000319146	0.003605135	5.0291E-06	0.000436829	8.18791E-09	4.07925E-07	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+scrambled oligos	1	1	1	1	1	1	1	1	
RAB5A + siRNA IRF3_1					0.19		0.2	0.18	
RAB5A + siRNA IRF3_2	0.44	0.3	0.4	0.45	0.13	0.12	0.19	0.25	
RAB5A + siRNA IRF3_3	0.56				0.33	0.5		0.1	
RAB5A + siRNA IRF3_4	0.11	0.05	0.03	0.02	0.01	0.005	0.02	0.05	
RAB5A + siRNA IRF3_5	0.18	0.13	0.03	0.03	0.01	0.003	0.04	0.03	
mean	0.3225	0.16	0.153333333	0.166666667	0.134	0.157	0.1125	0.122	
st dev	0.212661703	0.127671453	0.2136196	0.245424802	0.134461891	0.235115574	0.095699181	0.092032603	
t-test	0.000702084	0.000338216	0.002358058	0.004177477	5.28198E-07	0.000371414	1.58433E-06	2.45282E-08	

1885

1886

1887

**Table S2.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. 2B and statistics. In yellow, are the relative expression levels of differentially expressed CytoDR genes in RAB5A-MCF10.DCIS.com monolayers treated with the indicated small molecules: cGAS inhibitor, RU.521, the STING antagonist, H-151, or the TBK1/IKK inhibitor, MRT67307. The data are the ratio between the level of gene expression in each of the conditions tested relative to vehicle-treated RAB5A-expressing cells. In orange are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+vehicle	1	1	1	1	1	1	1	1	Values of the heatmap reported in Fig 2B.
RAB5A + RU.521	0.0345	0.134	0.06625	0.065	0.07733333	0.0525	0.1059	0.082666667	Data are expressed as mean of the independent experiments reported below
RAB5A + H-151	0.35	0.4925	0.38	0.35	0.6	0.3375	0.305	0.4075	
RAB5A + MRT67307	0.17	0.306666667	0.27	0.20333333	0.41	0.10533333	0.167	0.224666667	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental condition
RU.521_1	0.01	0.011	0.06		0.039	0.026		0.016	
RU.521_2	0.09	0.4	0.17	0.1	0.19	0.16	0.16	0.097	
RU.521_3	0.005	0.05	0.03	0.009	0.021	0.006	0.005	0.002	
RU.521_4	0.033	0.075	0.005	0.007	0.001	0.018	0.0085	0.001	
RU.521_5				0.009	0.013		0.006	0.03	
RU.521_6				0.2	0.2		0.35	0.35	
mean	0.0345	0.134	0.06625	0.065	0.07733333	0.0525	0.1059	0.082666667	
st dev	0.038957242	0.179278182	0.07272952	0.085273091	0.092031879	0.07213644	0.15178867	0.135696229	
t-test	1.80823E-05	0.002354544	0.00012956	1.64215E-05	2.08789E-06	0.00012102	0.00019192	1.46658E-05	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
H-151_1	0.49	0.5	0.61	0.62	0.4	0.34	0.42	0.39	
H-151_2	0.23	0.46	0.49	0.3	1.4	0.67	0.18	0.32	
H-151_3	0.34	0.5	0.18	0.22	0.31	0.2	0.29	0.28	
H-151_4	0.34	0.51	0.24	0.26	0.29	0.14	0.33	0.64	
mean	0.35	0.4925	0.38	0.35	0.6	0.3375	0.305	0.4075	
st dev	0.106770783	0.022173558	0.203797285	0.18293897	0.535474867	0.236977495	0.099498744	0.161529151	
t-test	0.001192754	2.29527E-05	0.008914612	0.005733683	0.232028772	0.011299627	0.000794192	0.005233051	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
MRT67307_1	0.46	0.47	0.38	0.29	0.2	0.16	0.33	0.41	
MRT67307_2	0.03	0.25	0.39	0.25	1	0.13	0.14	0.24	
MRT67307_3	0.02	0.2	0.04	0.07	0.03	0.026	0.031	0.024	
mean	0.17	0.306666667	0.27	0.20333333	0.41	0.10533333	0.167	0.224666667	
st dev	0.251197134	0.143643076	0.199248588	0.117189306	0.517976833	0.070323064	0.151317547	0.193456283	
t-test	0.029201032	0.014007594	0.023944375	0.007135649	0.187243523	0.002053112	0.010821143	0.020127931	

1894

1895

1896

1897

**Table S3.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. 2C and statistics. In yellow, are the relative expression levels of differentially expressed CytoDR genes in RAB5A-MCF10.DCIS.com monolayers silenced for the indicated genes with respect to monolayers treated with scrambled oligos. In orange, are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Values of the heatmap reported in Fig 2C.
RAB5A+scrambled oligos	1	1	1	1	1	1	1	1	1
RAB5A + siRNA IRF9	0.127666667	0.17	0.0475	0.126	0.0828	0.13133333	0.07828571	0.115	Data are expressed as mean of the independent experiments reported below
RAB5A + siRNA STAT 1/2	0.04	0.1025	0.0206	0.121	0.045625	0.09116667	0.031875	0.04125	
<hr/>									
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental
siRNA IRF9_1				0.23	0.05		0.07	0.05	
siRNA IRF9_2	0.096	0.24	0.11	0.26	0.08	0.13	0.08	0.43	
siRNA IRF9_3	0.23				0.28	0.36	0.15	0.08	
siRNA IRF9_4	0.36					0.09	0.08		
siRNA IRF9_5	0.01	0.35	0.06	0.12		0.2	0.15	0.07	
siRNA IRF9_6	0.03	0.03	0.01	0.01	0.003	0.003	0.008	0.03	
siRNA IRF9_7	0.04	0.06	0.01	0.01	0.001	0.005	0.01	0.03	
mean	0.127666667	0.17	0.0475	0.126	0.0828	0.13133333	0.07828571	0.115	
st dev	0.13894123	0.15165751	0.04787136	0.11802542	0.11514209	0.10402578	0.05768222	0.15565989	
t-test	2.1096E-05	0.00163245	3.4916E-05	7.7908E-05	5.8374E-05	1.8707E-05	1.1718E-08	3.4308E-05	
<hr/>									
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
siRNA STAT1/2_1				0.42	0.09		0.07	0.04	
siRNA STAT1/2_2				0.1	0.02		0.02	0.04	
siRNA STAT1/2_3	0.04	0.15	0.02	0.08	0.03	0.11	0.03	0.16	
siRNA STAT1/2_4	0.13				0.14	0.27	0.001	0.02	
siRNA STAT1/2_5	0.01			0.05		0.02	0.002	0.008	0.03
siRNA STAT1/2_6	0.01	0.21		0.03		0.06	0.15	0.11	0.02
siRNA STAT1/2_7	0.02	0.02	0.002	0.002	0.002	0.005	0.006	0.01	
siRNA STAT1/2_8	0.03	0.03	0.001	0.003	0.003	0.01	0.01	0.01	
mean	0.04	0.1025	0.0206	0.121	0.045625	0.09116667	0.031875	0.04125	
st dev	0.04560702	0.09287088	0.02051341	0.17292195	0.04834382	0.10748101	0.03849467	0.0494072	
t-test	5.1878E-08	0.00030251	4.616E-08	0.00034164	1.5498E-10	4.8571E-06	2.8535E-11	1.7475E-10	

1902  
1903  
1904  
1905

**Table S4.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. S3A and statistics. In yellow are the relative expression levels of differentially expressed CytoDR genes in RAB5A-expressing MCF10.DCIS.com monolayers treated with the indicated small molecules. The data are the ratio between the level of gene expression in each of the conditions tested relative to vehicle-treated RAB5A-expressing cells. In orange are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Values of the heatmap reported in Fig S3A.
RAB5A+vehicle	1	1	1	1	1	1	1	1	
RAB5A + Dynasore	0.12	0.176666667	0.173333333	0.123333333	0.126666667	0.093333333	0.126666667	0.092	Data are expressed as mean of the independent experiments reported below
RAB5A + PD0325901	0.403333333	0.133333333	0.136666667	0.286666667	0.23	0.813333333	0.283333333	0.44	
<hr/>									
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental conditions
Dynasore_1	0.25	0.4	0.46	0.32	0.34	0.24	0.34	0.26	
Dynasore_2	0.09	0.09	0.04	0.03	0.03	0.03	0.03	0.01	
Dynasore_3	0.02	0.04	0.02	0.02	0.01	0.01	0.01	0.006	
mean	0.12	0.176666667	0.173333333	0.123333333	0.126666667	0.093333333	0.126666667	0.092	
st dev	0.117898261	0.195021366	0.248461935	0.170391706	0.185022521	0.127410099	0.185022521	0.145506014	
t-test	0.00592996	0.018193338	0.028816622	0.01235938	0.01463365	0.006518215	0.01463365	0.008451542	
<hr/>									
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
PD0325901_1	0.31	0.16	0.12	0.27	0.2	1	0.35	0.41	
PD0325901_2	0.42	0.11	0.16	0.33	0.35	0.84	0.32	0.43	
PD0325901_3	0.48	0.13	0.13	0.26	0.14	0.6	0.18	0.48	
mean	0.403333333	0.133333333	0.136666667	0.286666667	0.23	0.813333333	0.283333333	0.44	
st dev	0.086216781	0.025166115	0.02081666	0.037859389	0.108166538	0.201328918	0.090737717	0.036055513	
t-test	0.006888006	0.000280947	0.000193739	0.000937626	0.006513639	0.249521226	0.005300978	0.001378945	

1906  
1907  
1908  
1909  
1910  
1911

1912  
1913

1914  
1915  
1916  
1917  
1918  
1919  
1920

**Table S5.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. S3A and statistics. In yellow, are the relative expression levels of differentially expressed CytoDR genes in RAB5A-MCF10.DCIS.com monolayers treated with the indicated small molecules. The data are the ratio between the level of gene expression in each of the conditions tested relative to vehicle-treated RAB5A-expressing cells. In orange, are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+vehicle	1	1	1	1	1	1	1	1	Values of the heatmap reported in Fig S5E.
RAB5A + MK886	0.826666667	0.703333333	0.626666667	0.76	0.503333333	0.403333333	0.626666667	0.643333333	Data are expressed as mean of the independent experiments reported below
RAB5A + Blebbistatin	1.113333333	0.6	0.883333333	0.6425	0.79	0.636666667	0.51	0.77	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental conditions
MK886_1	0.61	0.7	0.6	1	0.67	0.51	0.68	0.82	
MK886_2	0.72	0.83	0.7	0.7	0.28	0.21	0.54	0.51	
MK886_3	1.15	0.58	0.58	0.58	0.56	0.49	0.66	0.6	
mean	0.826666667	0.703333333	0.626666667	0.76	0.503333333	0.403333333	0.626666667	0.643333333	
st dev	0.285365263	0.125033329	0.064291005	0.216333077	0.201080415	0.167729942	0.075718778	0.159478316	
t-test	0.403126283	0.054421354	0.009741002	0.194612734	0.050531604	0.02534414	0.013436011	0.060644258	
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
Blebbistatin_1	1.1	0.74	0.65	0.41	0.69	0.72	0.49	0.25	
Blebbistatin_2	1.5	0.56	1.15	0.86	0.81	0.33	0.45	0.13	
Blebbistatin_3	0.74	0.5	0.85	1	0.54	0.86	0.31	1.3	
Blebbistatin_4				0.3			0.79	1.4	
mean	1.113333333	0.6	0.883333333	0.6425	0.68	0.636666667	0.51	0.77	
st dev	0.380175398	0.12489996	0.251661148	0.339840649	0.135277493	0.274651294	0.201990099	0.672755528	
t-test	0.657037731	0.030996834	0.506258069	0.126093056	0.054726094	0.149034587	0.016712932	0.543208296	

1921  
1922

**Table S6.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. S6E and statistics. In yellow, are the relative expression levels of differentially expressed CytoDR genes in RAB5A-MCF10.DCIS.com monolayers treated with the indicated small molecules. The data are the ratio between the level of gene expression in each of the conditions tested relative to vehicle-treated RAB5A-expressing cells. In orange, are the mean, s.d., and t-test.

	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	
RAB5A+vehicle	1	1	1	1	1	1	1	1	Values of the heatmap reported in Fig S6E.
RAB5A + Latrunculin	0.515	1.07	0.505	0.62	1.09	0.66	0.58	0.535	Data are expressed as mean of the independent experiments reported below
<hr/>									
	IFI27	IFI44	IFI44L	IFI6	IFIT1	IFIT3	ISG15	OASL	Raw data of all experimental conditions
Latrunculin_1	0.6	1.46	0.44	0.76	1	0.54	0.76	0.66	
Latrunculin_2	0.43	0.68	0.57	0.48	1.18	0.78	0.4	0.41	
mean	0.515	1.07	0.505	0.62	1.09	0.66	0.58	0.535	
st dev	0.120208153	0.551543289	0.091923882	0.197989899	0.127279221	0.169705627	0.254558441	0.176776695	
t-test	0.110450811	0.886938768	0.083120958	0.22472066	0.5	0.216000387	0.257762117	0.167182131	

1932  
1933  
1934  
1935  
1936  
1937

**Table S7.**

Relative expression levels of CytoDR genes presented as in the heatmap shown in Fig. S10E and statistics. In yellow, are the relative expression levels of differentially expressed CytoDR genes in RAB5A-MCF10.DCIS.com monolayers silenced for the indicated genes with respect to monolayers treated with scrambled oligos. In orange, are the mean, s.d., and t-test.

	CDH2	MMP13	ZEB1	
RAB5A+scrambled oligos	1	1	1	Values of the heatmap reported in Fig S10A.
RAB5A + siRNA YAP/TAZ	0.245	0.09	0.33	Data are expressed as mean of the independent experiments reported below
<hr/>				
<hr/>				
	CDH2	MMP13	ZEB1	Raw data of all experimental conditions
RAB5A+scrambled oligos	1	1	1	
RAB5A + siRNA YAP/TAZ_1	0.41	0.17	0.36	
RAB5A + siRNA YAP/TAZ_2	0.42		0.32	
RAB5A + siRNA YAP/TAZ_3	0.09	0.07	0.31	
RAB5A + siRNA YAP/TAZ_4	0.06	0.03	0.32	
mean	0.245	0.09	0.3275	
st dev	0.19672316	0.07211103	0.02217356	
t-test	0.00459395	0.0020866	9.8715E-06	

1938  
1939

1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
**References**

85. Palamidessi, A. et al. Unjamming overcomes kinetic and proliferation arrest in terminally differentiated cells and promotes collective motility of carcinoma. *Nat Mater* **18**, 1252-1263 (2019).

86. Sachs, N. et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. *Cell* **172**, 373-386 e310 (2018).

87. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21 (2013).

88. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

89. Sergushichev, A.A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. *bioRxiv*, 060012 (2016).

90. Della Chiara, G. et al. Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. *Nat Commun* **12**, 2340 (2021).

91. He, D.C., Nickerson, J.A. & Penman, S. Core filaments of the nuclear matrix. *J Cell Biol* **110**, 569-580 (1990).

92. Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114-2120 (2014).

93. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754-1760 (2009).

94. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079 (2009).

95. Kharchenko, P.V., Tolstorukov, M.Y. & Park, P.J. Design and analysis of ChIP-seq experiments for DNA-binding proteins. *Nat Biotechnol* **26**, 1351-1359 (2008).

96. Hahne, F. & Ivanek, R. Visualizing Genomic Data Using Gviz and Bioconductor. *Methods Mol Biol* **1418**, 335-351 (2016).

97. Ramirez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res* **44**, W160-165 (2016).

98. Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. 265-273 (Springer International Publishing, Cham; 2018).

99. Hu, M. et al. Regulation of in situ to invasive breast carcinoma transition. *Cancer cell* **13**, 394-406 (2008).

100. Gioia, U. et al. Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs. *Sci Rep* **9**, 6460 (2019).

101. Gyori, B.M., Venkatachalam, G., Thiagarajan, P., Hsu, D. & Clémént, M. OpenComet: An automated tool for comet assay image analysis. *Redox Biology* **2**, 457 - 465 (2014).

102. Schneider, C.A., Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* **9**, 671-675 (2012).

103. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**, 676-682 (2012).

104. Wahlby, C., Lindblad, J., Vondrus, M., Bengtsson, E. & Bjorkesten, L. Algorithms for cytoplasm segmentation of fluorescence labelled cells. *Anal Cell Pathol* **24**, 101-111 (2002).

105. Lim, J.S. *Two-dimensional signal and image processing*. (Prentice Hall, Englewood Cliffs, N.J.; 1990).

106. Meyer, F. Topographic distance and watershed lines. *Signal Processing* **38**, 113-125 (1994).

107. Jolliffe, I.T. & Cadima, J. Principal component analysis: a review and recent developments. *Philos Trans A Math Phys Eng Sci* **374**, 20150202 (2016).

108. Crocker, J.C. & Grier, D.G. Methods of Digital Video Microscopy for Colloidal Studies. *Journal of Colloid and Interface Science* **179**, 298-310 (1996).

1988 109. Thielicke, W. & Sonntag, R. Particle Image Velocimetry for MATLAB: Accuracy and enhanced  
1989 algorithms in PIVlab. *Journal of Open Research Software* **9**(1), (2021).  
1990 110. Beznoussenko, G.V. *et al.* Transport of soluble proteins through the Golgi occurs by diffusion via  
1991 continuities across cisternae. *Elife* **3** (2014).  
1992 111. Beznoussenko, G.V., Ragnini-Wilson, A., Wilson, C. & Mironov, A.A. Three-dimensional and immune  
1993 electron microscopic analysis of the secretory pathway in *Saccharomyces cerevisiae*. *Histochem  
1994 Cell Biol* **146**, 515-527 (2016).  
1995 112. Beznoussenko, G.V. & Mironov, A.A. Correlative video-light-electron microscopy of mobile  
1996 organelles. *Methods Mol Biol* **1270**, 321-346 (2015).  
1997 113. Koeberle, A. *et al.* MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits  
1998 cyclooxygenase-1 activity and suppresses platelet aggregation. *Eur J Pharmacol* **608**, 84-90 (2009).  
1999

2000 **Other Supplementary Materials for this manuscript include the following:**

2001 **Movies S1 to S9**

2002 **Movie S1.**

2003 Control (CTR) or RAB5A-MCF10.DCIS.com monolayers expressing mCherry-H2B treated with hypotonic  
2004 solution were monitored by fluorescence time-lapse microscopy over a 48 hours period. Pictures were taken  
2005 every 15 minutes (see Fig. S2D). Scale bar, 10  $\mu$ m.  
2006

2007 **Movie S2.**

2008 Control or RAB5-expressing HaCat monolayers were seeded at a jamming density, serum starved for 2  
2009 days, doxycycline-treated and monitored by time-lapse phase-contrast microscopy in the presence or the  
2010 absence of EGF (100 ng/ml). Frames were acquired with every 5 min over a period of 48 hours (see Fig.  
2011 S3C-E). Scale bar, 100  $\mu$ m.  
2012

2013 **Movie S3.**

2014 RAB5A promotes cell fluctuations in confluent monolayer. Space and time cell fluctuations were monitored  
2015 in MCF-10A cells stably expressing EGFP-E-cadherin by fluorescence time-lapse microscopy over a 24  
2016 hours period. Pictures were taken every 5 min and random pseudo colors are selected for different cell  
2017 identities (see Fig. 2E-G). Scale bar, 20  $\mu$ m.  
2018

2019 **Movie S4.**

2020 Nuclear segmentation and tracking of nuclear shape changes. Control and RAB5A-MCF10A expressing  
2021 mCherry-H2B were monitored by fluorescence time-lapse microscopy over a 24 hours period. Pictures  
2022 were taken every 10 min. The upper panels show randomly picked cell nuclei in which the continuous green  
2023 lines with different shades of green represent the corresponding fluctuating profiles of nuclear contours  
2024 obtained via nuclear segmentations (see Fig. 2H-I). In the bottom magnified panels, the red lines indicate  
2025 the representative fluctuating profiles of nuclear contours of control and RAB5A-MCF10A cells in a  
2026 monolayer. Scale bar, 4  $\mu$ m.  
2027

2028 **Movie S5.**

2029 Control MCF10.DCIS.com monolayers expressing mCherry-H2B were transfected with EGFP-cGAS. After  
2030 defining the region of interest, pre bleach images were collected for 30 seconds at a rate of 5 seconds per  
2031 timepoint. Photobleaching was performed using UltraVIEW PK Device as a bleaching device on a small  
2032 spot over the nuclear envelope. Images were captured for 300 seconds at a rate of 5 seconds per timepoint  
2033 (see Fig. S5A). Scale bar, 8  $\mu$ m.  
2034

2035 **Movie S6.**

2036 Control and RAB5A-MCF10.DCIS.com monolayers expressing EGFP-3NLS were seeded at jamming  
2037 density. After treatment with doxycycline to induce transgene expression, monolayers were monitored by  
2038 fluorescence time-lapse microscopy over a 30 hours period. Picture were taken every 15 min. The leakage  
2039 of EGFP-3NLS into the cytoplasm is indicative of NE ruptures (see Fig. 3D-E) Scale bar, 15  $\mu$ m.  
2040

2042

**Movie S7.**

2043 Living breast cancer organoids labelled with NucLight and embedded into Matrigel were monitored by  
2044 fluorescence time-lapse microscopy over a period of 24 hours. Pictures were taken every 15 min. (see Fig  
2045 S10A-C). Scale Bar, 8  $\mu$ m.

2046

2047

**Movie S8.**

2048 3D rendering of five living breast cancer organoids labelled with NucLight and embedded into Matrigel were  
2049 monitored by fluorescence time-lapse microscopy over a period of 24 hours. Pictures were taken every 15  
2050 min. The size of each box along the x- and y-directions corresponds to 200  $\mu$ m. In the bottom panels, thin  
2051 blue, orange and yellow curves are the temporal evolution of the x, y and z components of the angular  
2052 velocity associated with the rotation of the organoid depicted in the box above each panel, respectively.  
2053 Thick black curves represent the angular speed, *i.e.*, the modulus of the angular velocity. Organoids are  
2054 categorized as “rotating” if their average angular speed is larger than 0.03 cycles/h, as “non rotating”  
2055 otherwise (see Fig S10A-B).

2056

2057

**Movie S9.**

2058 A semi-automated image analysis pipeline to quantify the location of the  $\gamma$ H2AX expressing cells in the  
2059 tumoral ductaladenocarcinoma regions. A deep learning based nuclear segmentation (Stardist)<sup>98</sup> was  
2060 employed to segment individual nuclei and identified the centroid positions of each nuclei in the image  
2061 frame. A semi-automated analysis was used to identify the location of whole area, the core region and the  
2062 outer margin of the ductaladenocarcinoma. An automated histogram-based thresholding in each frame to  
2063 identify regions with high expression of  $\gamma$ H2AX signal, above the threshold applied. Isolated small spots  
2064 were removed as noise. Nuclei that display either a positive or weak/absent (below the arbitrary established  
2065 threshold levels)  $\gamma$ H2AX signal were identified. For each case, we quantified the total number of nuclei, the  
2066 number of nuclei with strongly positive or weak/no  $\gamma$ H2AX signal in the tumor core, tumor surface and in  
2067 the whole tumoral areas and computed the percentage of nuclei with strongly positive  $\gamma$ H2AX signal in the  
2068 core region, tumor front regions and in the whole tumor region over 9 independent cases (see Materials  
2069 and Methods for details).

2070

2071

**RNA-seq data**

2072 RNA-seq data of MCF10A and MCF10.DCIS.com cells and of organoids are being submitted respectively  
2073 to Gene Expression Omnibus (GEO) and European Genome-phenome Archive (EGA) and are available  
2074 upon request.

2075

2076

2077